| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
sNDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
sNDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
sNDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
Karyopharm Therapeutics Inc.
$1.86
-0.09 (-4.59%)
C 51Pipeline Score Fair Value Pharma · Commercial
Market Cap
42.19 M
EPS
-9.91
P/E Ratio
-
Value Trade
3.57 M
-3.63 %
Week
-73.77 %
1 Month
-79.26 %
3 Month
-81.53 %
6 Month
-94.31 %
5 Year
-96.95 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
909.10 K
52 Week Range
1.79 - 10.99
% held by Insiders
19.12 %
% held by Institutions
81.8 %
Enterprise Value
-22.92 M
Total Shares
22.68 M
Short %
41.18 %
Float Shares
17.98 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Karyopharm Therapeutics Inc.
1338Total events
3Upcoming
304Tier-1 (high impact)
2012 – 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T1Full Results
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Runway Guidance UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | selinexor | Phase 3 topline data readout | Phase 3 | — | – | – | – |
2026-06-30 | selinexor | Phase 3 topline data readout | Phase 3 | — | – | – | – |
2026-06-30 | selinexor | Phase 3 topline data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
C51
Pipeline Score $130M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored2.9x
rNPV / MCap Top 81%
Micro Cap (rank 178 of 933)
Percentile RankKaryopharm Therapeutics Inc. carries a moderate pipeline score (51/100), with $2.2B risk-adjusted pipeline value, led by Selinexor in Multiple Myeloma (Phase 3), across $168B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selinexor Small molecule | Myelofibrosis | Phase 3 | NCT04562870 | 42% | $968M | ACTIVE NOT_RECRUITING | 523 | FAST | C (55) | Sep 1, 2026 | MODERATE_RISK | LOW Jul 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
selinexor Fast Track | myelofibrosis | Phase 3 | 2026-06-02 | near doubling of patients achieving spleen volume reduction at week 24; >50% reduction of risk of death versus Ruxolitinib; more patients achieving ≥20% reductions in VAF as early as week 24 Read More | Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology Read More | |
selinexor Fast Track | myelofibrosis | Phase 3 | 2026-06-02 | near doubling of patients achieving spleen volume reduction at week 24; >50% reduction of risk of death versus Ruxolitinib; more patients achieving ≥20% reductions in VAF as early as week 24 Read More | Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology Read More | |
selinexor Fast Track | myelofibrosis | Phase 3 | 2026-06-02 | near doubling of patients achieving spleen volume reduction at week 24; >50% reduction of risk of death versus Ruxolitinib; more patients achieving ≥20% reductions in VAF as early as week 24 Read More | Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KPTI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KPTI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KPTI▼ -7.5%on this news
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
Karyopharm Therapeutics Inc. will report its second quarter 2026 financial results on August 13, 2026. A conference call will be held at 8:00 a.m. ET to discuss these results and other updates. The company is known for its innovative cancer therapies, particularly XPOVIO, which is approved in multiple countries.
Read more →KPTIKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
Karyopharm Therapeutics Inc. will participate in a virtual fireside chat on June 8, 2026, featuring Dr. Robert Coleman, a leading expert in gynecologic oncology. The event will discuss the company's advancements in cancer therapies, particularly in endometrial cancer. A replay will be available on their website after the event.
Read more →KPTIKaryopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm Therapeutics announced that its late-breaking abstract from the Phase 3 SENTRY trial has been selected for an oral presentation at the 2026 EHA Congress. The trial evaluates the combination of selinexor and ruxolitinib in myelofibrosis patients, showing promising results in spleen volume reduction and overall survival predictions. The findings highlight the potential of selinexor to enhance treatment outcomes beyond traditional JAK inhibitors.
Read more →KPTIKaryopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
Karyopharm Therapeutics announced positive results from its Phase 3 SENTRY trial, demonstrating that the combination of selinexor and ruxolitinib significantly improved patient outcomes in myelofibrosis. The trial showed a near doubling of patients achieving spleen volume reduction at week 24 and a promising overall survival signal. The results were presented at the ASCO 2026 Annual Meeting and published in the Journal of Clinical Oncology.
Read more →KPTI▲ +7.9%on this newsshared move
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
Karyopharm Therapeutics will host an investor conference call on June 2, 2026, featuring Dr. John Mascarenhas, who will discuss the Phase 3 SENTRY trial results. This follows his presentation at the 2026 ASCO Annual Meeting. The call aims to provide insights into the combination therapy of selinexor and ruxolitinib for myelofibrosis.
Read more →KPTI▲ +7.9%on this newsshared move
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics has granted 1,200 restricted stock units (RSUs) to a newly-hired employee as part of its 2022 Inducement Stock Incentive Plan. This award, effective May 31, 2026, will vest over three years, contingent on the employee's continued service. The company is known for its innovative cancer therapies, particularly XPOVIO.
Read more →KPTIKaryopharm to Participate at the 2026 Jefferies Global Healthcare Conference
Karyopharm Therapeutics Inc. will participate in the 2026 Jefferies Global Healthcare Conference with a fireside chat scheduled for June 4, 2026. The event will feature the company's senior management discussing their innovative cancer therapies, including XPOVIO. A live webcast will be available for those unable to attend in person.
Read more →KPTIKaryopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment – Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expect
Karyopharm Therapeutics Inc. reported its first quarter financial results for 2026, highlighting total revenue of $35.1 million, primarily driven by net product revenue of $29.2 million from XPOVIO. The company announced the completion of enrollment for its Phase 3 XPORT-EC-042 trial in endometrial cancer and the acceptance of SENTRY trial results for a late-breaking presentation at the upcoming ASCO meeting. Despite some challenges such as decreased demand and unmet trial endpoints, Karyopharm maintains an optimistic outlook with several important data readouts expected in mid-2026.
Read more →KPTIKaryopharm to Participate at Upcoming Investor Conferences
Karyopharm Therapeutics Inc. announced participation in two upcoming investor conferences in May 2026. The events include fireside chats at the H.C. Wainwright 4th Annual BioConnect Investor Conference and the RBC 2026 Global Healthcare Conference. Live webcasts will be available on the company's website, highlighting its commitment to cancer therapy innovation.
Read more →KPTIKaryopharm to Report First Quarter 2026 Financial Results on May 14, 2026
Karyopharm Therapeutics Inc. will report its first quarter 2026 financial results on May 14, 2026. The management team will host a conference call at 8:00 a.m. ET to discuss the results and provide company updates. Interested parties can access the call via phone or through a live audio webcast.
Read more →KPTIKaryopharm
Karyopharm Therapeutics Inc. announced that their late-breaking abstract was accepted for oral presentation at the 2026 ASCO Annual Meeting. The presentation will showcase results from the Phase 3 SENTRY trial, focusing on the efficacy of selinexor combined with ruxolitinib in myelofibrosis patients. The event is scheduled for June 2, 2026, and reflects Karyopharm's continued commitment to developing innovative cancer therapies. Presenting findings from the trial, which has important implications for myelofibrosis treatment, signifies a vital step in advancing cancer care.
Read more →KPTI▼ -18.3%on this news
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
Karyopharm Therapeutics announced that its Phase 3 SENTRY trial met its first co-primary endpoint, showing significant improvement in spleen volume reduction for patients with myelofibrosis treated with selinexor and ruxolitinib. Although the trial did not meet its second endpoint regarding symptom improvement, it indicated a promising signal for overall survival. The company plans to discuss these results with the FDA and potentially file a supplemental new drug application.
Read more →KPTI▼ -18.3%on this newsshared move
BELIEVERS IN THE EXTRAORDINARY Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - While Similar Symptom Impr
Karyopharm Therapeutics announced positive results from its Phase 3 SENTRY trial for myelofibrosis, demonstrating significant spleen volume reduction for patients treated with a combination of selinexor and ruxolitinib. The trial met its first co-primary endpoint while indicating a promising signal in overall survival. However, the second co-primary endpoint regarding symptom improvement was not statistically significant. Overall, the results suggest a potential effective treatment advance for myelofibrosis patients, as no new safety issues were reported.
Read more →KPTI▼ -18.3%on this newsshared move
Karyopharm Announces $30 Million Private Placement with RA Capital
Karyopharm Therapeutics has announced a $30 million private placement with RA Capital Management, which may increase to $44 million if accompanying warrants are exercised. The funds will support ongoing clinical trials and corporate activities. The placement is expected to close on March 26, 2026, pending customary conditions.
Read more →KPTIKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics has granted 1,450 restricted stock units (RSUs) to two new employees as part of its 2022 Inducement Stock Incentive Plan. The RSUs will vest over three years, contingent on the employees' continued service. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Karyopharm's commitment to attracting talent in the oncology field.
Read more →KPTI▲ +21.3%on this news
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics reported its financial results for Q4 and full year 2025, highlighting a total revenue of $146 million. The company is poised for key clinical milestones in 2026, with top-line data from the Phase 3 SENTRY trial in myelofibrosis expected in March and from the XPORT-EC-042 trial in endometrial cancer anticipated by mid-2026. Despite a significant net loss, Karyopharm remains focused on expanding its impact in cancer therapies.
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Karyopharm Therapeutics Inc. has announced that it will report its fourth quarter and full year 2025 financial results on February 12, 2026. The management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss these results and provide other company updates. Karyopharm is recognized for its innovative cancer therapies and has a strong pipeline targeting various cancers.
Read more →KPTI▼ -5.6%on this news· ran to -23% by day 3
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Tr
Karyopharm Therapeutics has announced its preliminary unaudited revenue estimates for 2025, with total revenue expected to reach approximately $145 million. The company is preparing for a significant 2026, with top-line data from the Phase 3 SENTRY trial in myelofibrosis expected in March, and additional data from the XPORT-EC-042 trial in mid-2026. There is optimism around the potential for transformative patient outcomes, supported by expanded market access for selinexor. However, the company acknowledges the uncertainties inherent in preliminary data and faces pressures from increased competition in the market.
Read more →KPTIKaryopharm to Participate in Baird's Biotech Discovery Series
Karyopharm Therapeutics Inc. will participate in Baird's Biotech Discovery Series on December 10, 2025. The event features a virtual fireside chat with the company's senior management and Dr. Claire Harrison, an expert in myelofibrosis. A live webcast will be available on the company's investor website.
Read more →KPTIKaryopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Karyopharm Therapeutics Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 4, 2025. The senior management team will engage in a fireside chat at 10:30 a.m. ET in New York. A live webcast will be available on the company's investor website.
Read more →KPTIKaryopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics reported its third quarter 2025 financial results, highlighting a total revenue of $44 million, an increase from the previous year. The company reaffirmed its revenue guidance for 2025 and announced the completion of enrollment in the Phase 3 SENTRY trial for myelofibrosis. Despite these positive developments, Karyopharm reported a slight increase in net loss and a significant decrease in cash position compared to the previous year.
Read more →KPTIKaryopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
Karyopharm Therapeutics Inc. will report its third quarter 2025 financial results on November 3, 2025. A conference call is scheduled for 8:00 a.m. ET on the same day, where management will discuss the results and company updates. The company is known for its innovative cancer therapies, including the XPO1 inhibitor, XPOVIO.
Read more →KPTIKaryopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics has announced strategic financing transactions that will provide $100 million to support its growth and extend its cash runway into the second quarter of 2026. This funding is crucial as the company prepares for the top-line data readout from its Phase 3 SENTRY trial in myelofibrosis, expected in March 2026. The company anticipates total revenue for Q3 2025 to be between $42 and $44 million.
Read more →KPTIBELIEVERS IN THE EXTRAORDINARY Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofi
Karyopharm Therapeutics announced strategic financing transactions aimed at bolstering its growth, yielding $100 million in additional capital. This funding will extend the company's cash runway into the second quarter of 2026, allowing it to support ongoing clinical trials, including the pivotal Phase 3 SENTRY trial in myelofibrosis. The company anticipates top-line data from this trial by March 2026, maintaining optimism about its novel selinexor combination therapy. However, the financing also involves the issuance of new shares, which may dilute existing shareholders.
Read more →KPTIKaryopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics has completed enrollment in its Phase 3 SENTRY trial, which evaluates the combination of selinexor and ruxolitinib in patients with JAKi-naïve myelofibrosis. The trial aims to assess the effectiveness of this combination therapy, with top-line results expected in March 2026. This milestone represents a potential advancement in treatment options for myelofibrosis patients.
Read more →KPTIKaryopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress – New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Antic
Karyopharm Therapeutics reported its financial results for Q2 2025, indicating a total revenue of $37.9 million and a 6% increase in U.S. XPOVIO net product revenue. The company anticipates closing new patient screening for its Phase 3 SENTRY trial in myelofibrosis this week, with top-line results expected by March 2026. Despite a revenue decline compared to the previous year, the company is optimistic about its clinical trial progress and ongoing strategic financial initiatives.
Read more →KPTIKaryopharm to Report Second Quarter 2025 Financial Results on August 11, 2025
Karyopharm Therapeutics Inc. has announced that it will report its financial results for the second quarter of 2025 on August 11, 2025. The company will host a conference call at 8:00 a.m. ET to discuss these results along with other updates regarding the business. Investors can access the call through a dedicated phone line or by participating in a live audio webcast available on their website.
Read more →KPTI▼ -9%on this news
Confidential Investor Presentation July 2025 2025 KARYOPHARM THERAPEUTICS INC. | CONFIDENTIAL & PROPRIETARY Forward-Looking Statements and Disclaimers 2 This presentation contains forward-looking statements within the me
Karyopharm Therapeutics is focused on advancing its pipeline, particularly in myelofibrosis, with selinexor showing promise based on preliminary data. The company anticipates a peak annual revenue opportunity of up to $1 billion if regulatory approvals are attained. The Phase 3 SENTRY trial is reportedly near full enrollment and has highlighted potential advantages of selinexor over existing therapies. However, the company acknowledges several risks, including market conditions and regulatory challenges, which could impact future operations and timelines.
Read more →KPTIKaryopharm to Present at the Jefferies Global Healthcare Conference
Karyopharm Therapeutics Inc. has announced that its senior management will present at the Jefferies Global Healthcare Conference on June 5, 2025. This event, set to begin at 3:10 p.m. ET in New York, provides an important platform for the company to share updates on its cancer therapies. Interested parties may access a live webcast of the presentation and view the accompanying slides online, with a replay available after the event.
Read more →KPTIKaryopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
Karyopharm Therapeutics Inc. announced that its senior management team will participate in the 2025 RBC Capital Markets Global Healthcare Conference. The event includes a fireside chat scheduled for May 21 at 10:00 a.m. ET in New York, NY. A live webcast will be available for those unable to attend the event in person, providing ongoing access to the discussion. This participation reflects Karyopharm's commitment to engaging with investors and stakeholders on its cancer therapies.
Read more →KPTIKaryopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
Karyopharm Therapeutics announced that its abstract on selinexor will be presented at the 2025 European Hematology Association Annual Meeting. The presentation will include data from the Phase 2 study showing that selinexor monotherapy is effective in reducing spleen volume and improving symptoms in heavily pretreated myelofibrosis patients. The trial demonstrated promising results, indicating potential evidence for disease modification with selinexor. This marks a significant opportunity for Karyopharm to highlight the benefits of selinexor in a challenging patient population.
Read more →KPTIKaryopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilizatio
Karyopharm Therapeutics reported its financial results for Q1 2025, highlighting advancements in its myelofibrosis drug selinexor. The company announced improved clinical efficacy indicators from its Phase 2 XPORT-MF-035 trial, suggesting selinexor's potential when combined with ruxolitinib in patients. The ongoing Phase 3 SENTRY trial has cleared a futility analysis and is nearly fully enrolled, contributing to a positive outlook. Despite these advancements, net product revenue faced challenges due to increased product return reserves.
Read more →KPTIKaryopharm to Report First Quarter 2025 Financial Results on May 12, 2025
Karyopharm Therapeutics Inc. has announced that it will report its financial results for the first quarter of 2025 on May 12, 2025. A conference call is scheduled to take place at 4:30 p.m. ET on the same day, during which the management team will discuss the financial results and provide additional company updates. Investors can access the call via a dedicated phone line or through an audio webcast on the company's website.
Read more →KPTIKaryopharm Announces 1-for-15 Reverse Stock Split
Karyopharm Therapeutics Inc. has announced a 1-for-15 reverse stock split of its common stock, to take effect on February 25, 2025. This decision was approved by stockholders to help the company meet the Nasdaq minimum bid price requirement. The move will reduce the number of outstanding shares significantly, from approximately 126.2 million to 8.4 million. Following the split, the company plans to make necessary adjustments to its equity incentive plans and outstanding convertible notes.
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress – Total Revenue of $145 Million and U.S. XPOVIO (seline
Karyopharm Therapeutics reported its financial results for Q4 and full-year 2024, revealing total revenues of $145 million, with U.S. XPOVIO contributing $113 million. The company announced modifications to its Phase 3 XPORT-EC-042 trial, focusing on TP53 wild-type endometrial cancer, following discussions with the FDA. The trial's sample size is increased to 276 patients, with top-line data now expected in mid-2026. Additionally, guidance for 2025 revenue is set between $140 million to $155 million, highlighting ongoing commercial and clinical strategic progress.
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Karyopharm Therapeutics Inc. will report its fourth quarter and full year 2024 financial results on February 19, 2025. The announcement includes a schedule for a conference call and audio webcast at 8:00 a.m. ET to discuss the financial outcomes and other updates. Investors can access the call via provided phone numbers or view a live audio webcast on the company’s website.
Read more →KPTI▼ -6.4%on this news
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives – Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor
Karyopharm Therapeutics Inc. announced preliminary unaudited total revenue estimates for 2024 at approximately $145 million and outlined strategic objectives for 2025. The company is focused on the upcoming top-line data readout from the Phase 3 SENTRY trial for selinexor in myelofibrosis, expected in the second half of 2025. Additionally, with leadership changes and expanded global patient access for selinexor, Karyopharm is positioning itself to improve treatment options in multiple myeloma and myelofibrosis. Despite some challenges in demand and revenue adjustments, the company maintains a positive outlook.
Read more →KPTI▲ +20%on this news
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
Karyopharm Therapeutics Inc. has appointed Lori Macomber as its new Chief Financial Officer, effective January 3, 2025. Ms. Macomber brings over 20 years of financial management experience from various notable life science companies. Her role will focus on overseeing the company’s financial activities, particularly to drive revenue growth for XPOVIO and aid in clinical pipeline development. She has been granted stock options and restricted stock units as part of her inducement awards linked to her employment with Karyopharm.
Read more →KPTIKaryopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
Karyopharm Therapeutics has appointed Brendan Strong as its new Senior Vice President of Investor Relations and Corporate Communications. His background includes previous roles in investor relations and corporate consulting, which Karyopharm anticipates will enhance their communication as they pursue key milestones in 2025. Strong's enthusiasm for the company's late-stage pipeline and its mission highlights a potentially transformative year ahead for the organization.
Read more →KPTIBELIEVERS IN THE EXTRAORDINARY Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Karyopharm Therapeutics announced an update on its endometrial cancer program, revealing it is in discussions with the FDA about implications for its Phase 3 XPORT-EC-042 trial. The company will not present on the topic at the Piper Sandler Healthcare Conference but intends to share further updates after the FDA meeting. The XPORT-EC-042 trial is evaluating selinexor as a maintenance therapy for patients with advanced or recurrent endometrial cancer, and aims to enroll up to 220 patients.
Read more →KPTIKaryopharm Therapeutics Provides Endometrial Cancer Program Update
Karyopharm Therapeutics Inc. announced it is engaging with the FDA regarding its endometrial cancer program and the Phase 3 XPORT-EC-042 trial. The update follows a decision not to discuss the endometrial cancer program at the Piper Sandler 36th Annual Healthcare Conference. The XPORT-EC-042 trial will evaluate selinexor as a maintenance therapy for patients with advanced or recurrent endometrial cancer, aiming to enroll up to 220 patients. Karyopharm plans to provide further updates following its discussions with the FDA.
Read more →KPTIKaryopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm Therapeutics Inc. has announced its participation in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3, 2024, at 11:30 a.m. ET in New York, NY. The company's senior management will engage in a fireside chat during the event. A live webcast of this session will be available on Karyopharm's investor website, with a replay option following the event. This participation underscores Karyopharm's commitment to transparency and investor relations.
Read more →KPTIKaryopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Karyopharm Therapeutics has appointed Kristin Abate as its Chief Accounting Officer effective November 20, 2024. Abate, who has been with the company since July 2019, previously held the positions of Vice President, Accounting, Corporate Controller, and Assistant Treasurer. She also served as the interim principal financial officer and interim principal accounting officer. Abate has over 15 years of finance experience, including previous work at PricewaterhouseCoopers LLP.
Read more →KPTIKaryopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
Karyopharm Therapeutics has announced that data on their cancer therapy candidate, selinexor, will be presented at the 66th American Society of Hematology Annual Meeting from December 7-10, 2024. The presentations will focus on its efficacy in treating patients with relapsed or refractory multiple myeloma and myelofibrosis. This illustrates the company's commitment to advancing treatments in these disease areas. Selinexor is already approved for use in the U.S. and continues to be part of ongoing clinical trials.
Read more →KPTI▼ -9.4%on this news
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. reported its third quarter 2024 financial results, highlighting total revenue of $38.8 million, with U.S. XPOVIO net product revenue reaching $29.5 million. The company announced a significant change in the Phase 3 SENTRY trial’s primary endpoints, following discussions with the FDA. They also narrowed their full-year revenue guidance, while expressing optimism regarding ongoing demand for XPOVIO amidst a competitive market. Karyopharm continues to work towards expanding global access to their products and advancing their clinical pipeline.
Read more →KPTI▼ -9.4%on this news
BELIEVERS IN THE EXTRAORDINARY Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO (selinexor) Net Pro
Karyopharm Therapeutics Inc. reported its Q3 2024 financial results, announcing a total revenue of $38.8 million, reflecting growth over the same quarter in 2023. The company highlighted positive developments in its clinical pipeline, notably a change in the Phase 3 SENTRY trial endpoints that a key regulatory body has approved. Despite the revenue growth, Karyopharm faced a net loss of $32.1 million and an increase in interest expenses. The firm continues to navigate a competitive landscape while seeking to expand its product indications.
Read more →KPTI▲ +17.8%on this newsshared move
Targeting Disease at the Nuclear Pore Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) f
Karyopharm Therapeutics has announced a favorable change in the co-primary endpoint for the Phase 3 SENTRY Trial in myelofibrosis, now utilizing the Absolute Total Symptom Score (Abs-TSS) instead of Total Symptom Score Improvement of 50% (TSS50). This change follows alignment with the FDA and aims to provide a more accurate assessment of symptom improvements in patients. The Phase 1 trial of selinexor combined with ruxolitinib suggests improved efficacy, with a nearly 80% rate of spleen volume response. The company anticipates enrolling around 350 patients and expects to report top-line results in the second half of 2025.
Read more →KPTI▲ +17.8%on this newsshared move
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
Karyopharm Therapeutics Inc. has announced that it will report its third quarter 2024 financial results on November 5, 2024. The company will host a conference call and audio webcast at 8:00 a.m. ET to discuss the results and other updates. Investors can access the call by dialing the provided numbers or through a live audio webcast available on the company's website. An archived version of the webcast will be accessible shortly after the event.
Read more →KPTI▲ +17.8%on this newsshared move
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics has announced a significant change in the co-primary endpoint for its Phase 3 SENTRY Trial, substituting Total Symptom Score Improvement with Absolute Total Symptom Score following FDA feedback. The trial will now also focus on Spleen Volume Response Rate as a co-primary endpoint. The company plans to increase the sample size to about 350 participants to bolster the trial's statistical power. Promising preliminary data from a prior trial indicate a substantial improvement in symptom scores for patients receiving the combination treatment of selinexor and ruxolitinib, enhancing confidence in the upcoming results.
Read more →KPTIKaryopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
Karyopharm Therapeutics Inc. announced it will host a conference call on October 31, 2024, to share an update on the favorable study design of its pivotal Phase 3 SENTRY study for JAKi naive myelofibrosis. The call will feature leading experts in the field, including Dr. Raajit Rampal and Dr. John Mascarenhas. The event reflects Karyopharm's ongoing commitment to developing novel cancer therapies.
Read more →KPTIKaryopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics reported strong second-quarter 2024 financial results with total revenue of $42.8 million and net product revenue from XPOVIO reaching $28 million. The company showcased promising clinical data for selinexor in advanced/recurrent endometrial cancer, demonstrating significant median progression-free survival in exploratory subgroups. Notably, the company improved its capital structure with refinancing initiatives, providing a stable foundation for future growth amid ongoing competitive pressures in the market. However, Karyopharm anticipates challenges in patient enrollment for certain clinical trials and delays in data readouts due to unforeseen circumstances.
Read more →KPTIBELIEVERS IN THE EXTRAORDINARY Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO (selinexor) Net P
Karyopharm Therapeutics Inc. reported significant financial growth for the second quarter of 2024, achieving total revenues of $42.8 million. The net product revenue for their key drug XPOVIO reached $28.0 million amidst challenging market conditions. The company also boosted its 2024 revenue guidance and presented promising clinical trial results, particularly for selinexor in advanced endometrial cancer. However, rising R&D costs and a decrease in cash reserves are points of concern moving forward.
Read more →KPTI▼ -6.7%on this news· ran to -18% by day 3shared move
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
Karyopharm Therapeutics Inc. has announced its plans to report its financial results for the second quarter of 2024 on August 6, 2024. The announcement includes a scheduled conference call at 8:00 a.m. ET where the management team will discuss the financial outcomes and other updates. Investors can participate by calling in or accessing a live audio webcast, which will be available on the company's website.
Read more →KPTIKaryopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics has presented updated exploratory subgroup analyses from the SIENDO study, revealing promising progression-free survival (PFS) data for selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer. The analysis shows a median PFS of 28.4 months among those treated with selinexor compared to just 5.2 months for the placebo group. Additionally, the quality-adjusted time without symptoms or toxicity (Q-TWiST) metric indicates improved quality of life for patients receiving selinexor. Despite these positive findings, some primary analysis results were not clinically meaningful, signaling a need for further investigation.
Read more →KPTIKaryopharm to Participate at the Jefferies Global Healthcare Conference
Karyopharm Therapeutics Inc. (KPTI) has announced its participation in the Jefferies Global Healthcare Conference, where its senior management will engage in a fireside chat on June 5, 2024. This event is taking place in New York, NY, and will include a live webcast. The webcast will also be available for replay after the event, providing investors and stakeholders with access to important company insights.
Read more →KPTI▼ -7.3%on this news
Targeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress Announces Significant Refinancing Transactions and Amends Royalty Agreement with Health
Karyopharm Therapeutics announced its financial results for the first quarter of 2024, reporting total revenues of $33.1 million, a decrease from the previous year's $38.7 million. The company reaffirmed its revenue guidance for the year between $140 million and $160 million. Significant refinancing transactions extended debt maturities into 2028 and 2029, positioning the company for future growth amidst ongoing Phase 3 clinical trials. Karyopharm's pipeline includes promising new indications for its lead therapy, selinexor, although it reported a net loss of $37.4 million.
Read more →KPTI▼ -7.3%on this news
Targeting Disease at the Nuclear Pore Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 $148.0 Million (86%) of Exis
Karyopharm Therapeutics Inc. announced a series of refinancing transactions aimed at extending its debt maturities into 2028 and 2029. The company exchanged $148 million of existing convertible notes for new notes and secured a new $100 million term loan to bolster its balance sheet. These deals are expected to support Karyopharm's ongoing clinical trials and strategic goals, including the development of its lead product selinexor. The refinancing also includes a reduction in the royalty rate owed to HealthCare Royalty from 12.5% to a flat 7%.
Read more →KPTI▼ -7.3%on this news
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that its senior management will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference. The session is scheduled for May 15 at 9:30 a.m. ET and will be accessible via a live webcast. This event underscores Karyopharm's ongoing efforts to engage with investors and share insights into its cancer therapies.
Read more →KPTI▼ -7.3%on this news
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. reported its financial results for the first quarter of 2024, achieving total revenue of $33.1 million. The company reaffirmed its fiscal guidance for the year, with expected total revenues between $140 million and $160 million. Key developments include the addition of the XPOVIO product to China's National Reimbursement Drug List and an ongoing commitment to advancing its Phase 3 trials. Despite these positive aspects, Karyopharm faced a net loss of $37.4 million during the quarter, highlighting significant financial challenges.
Read more →KPTI▼ -7.3%on this news
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
Karyopharm Therapeutics Inc. has announced a significant refinancing initiative that includes extending the maturities of the majority of its debt into 2028 and 2029. The company exchanged a substantial amount of its existing convertible notes for new ones due in 2029 and secured a new senior secured term loan of $100 million due in 2028. These measures aim to strengthen its financial position as it approaches critical Phase 3 readouts. Additionally, the terms of a royal agreement were amended, lowering the royalty rate on its product selinexor, which is anticipated to enhance profitability for the company moving forward.
Read more →KPTIKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024
Karyopharm Therapeutics Inc. has announced that it will report its financial results for the first quarter of 2024 on May 8, 2024. The company will hold a conference call at 8:00 a.m. ET to discuss these results as well as additional company updates. Interested parties can access the call via a local or international phone number or through a live audio webcast through the company’s website.
Read more →KPTIKaryopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Karyopharm Therapeutics Inc. has announced that several abstracts featuring new data on selinexor will be presented at the 2024 American Society of Clinical Oncology Annual Meeting, taking place from May 31 to June 4 in Chicago. Notably, an updated presentation on the long-term follow-up of selinexor maintenance in TP53wt advanced or recurrent endometrial cancer has been accepted. The company’s Chief Medical Officer expressed excitement about progressing their phase three programs in endometrial cancer, myelofibrosis, and multiple myeloma, highlighting the company's commitment to addressing areas of high unmet patient need.
Read more →KPTI▲ +6.8%on this news· ran to +23% by day 1
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Karyopharm Therapeutics Inc. will have its senior management team participate in two prominent healthcare conferences. They are scheduled to present at the Barclays 26th Annual Global Healthcare Conference on March 13, 2024, and participate in the Leerink Partners Global Biopharma Conference on March 12, 2024. These events offer the company an opportunity to showcase its novel cancer therapies to a wider audience.
Read more →KPTI▼ -12.8%on this newsshared move
Targeting Disease at the Nuclear Poreh3 Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress Total Revenue of $146 Million and U.S. XPOVIO (selinexor) Net Product
Karyopharm Therapeutics Inc. reported its financial results for the fourth quarter and full year 2023, highlighting total revenue of $146 million. Despite a decrease in net product revenue and an increased net loss, the company remains hopeful due to anticipated Phase 3 trial results in 2025. Karyopharm's development pipeline shows promise, with guidance for revenues in 2024 set between $140 million and $160 million. Additionally, they report a cash runway extending to late 2025, allowing continued focus on clinical advancement.
Read more →KPTI▼ -12.8%on this newsshared move
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. reported its financial results for Q4 and the full year of 2023, highlighting total revenue of $146 million, which aligned with their guidance. The company is optimistic about upcoming top-line data readouts from three pivotal trials evaluating its product selinexor in 2025. Despite some setbacks, including a decrease in U.S. net product revenue to $112 million, Karyopharm forecasted revenue guidance for 2024 to be between $140 million and $160 million, indicating planning for sustained operations through 2025.
Read more →KPTI▼ -6.6%on this news
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Karyopharm Therapeutics Inc. has announced it will report its fourth quarter and full year 2023 financial results on February 29, 2024. A conference call and audio webcast will follow at 8:00 a.m. ET to discuss these financial results along with other company updates. The public can access the call via a designated phone number or through the company's investor website for those who prefer the audio webcast. Archived webcasts will be available shortly after the event.
Read more →KPTI▲ +11.9%on this news
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
Karyopharm Therapeutics has announced preliminary unaudited revenue figures for 2023, estimating total revenue at approximately $146 million, which aligns with the company's guidance. The firm is focused on advancing its pipeline, notably with selinexor for multiple myeloma, endometrial cancer, and myelofibrosis, expecting key clinical trial data to be reported in 2024. Despite facing challenges such as increased competition and regulatory changes impacting revenue, Karyopharm remains optimistic about its future growth and strategic objectives.
Read more →KPTI▲ +11.9%on this news
Targeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from
Karyopharm Therapeutics has announced its preliminary unaudited revenue for 2023, totaling approximately $146 million, in line with company expectations. The firm outlined its objectives for 2024, which include advancements in its late-stage pipeline and ongoing recruitment for pivotal Phase 3 studies evaluating selinexor in multiple myeloma, endometrial cancer, and myelofibrosis. Karyopharm is optimistic about the potential of selinexor as a novel treatment option and expects to provide further updates in 2024. The company is also positioned to maintain operational viability with a cash runway extending into late 2025.
Read more →KPTI▼ -7.6%on this newsshared move
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
Karyopharm Therapeutics Inc. is set to participate in the 42nd Annual J.P. Morgan Healthcare Conference, which will take place on January 10, 2024. The senior management will deliver a podium presentation followed by a Q&A session. Investors can access the live webcast and subsequent replay through the company's investor website, enhancing accessibility to their latest developments.
Read more →KPTI▼ -9.6%on this news
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
Karyopharm Therapeutics has presented promising data from a Phase 1 study of selinexor combined with ruxolitinib for treatment-naïve myelofibrosis patients at ASH 2023. The findings highlight strong durability in spleen volume reduction and symptom improvement, suggesting potential disease modification. With no new safety concerns reported, the combination therapy shows promise as a first-line treatment. Expert opinion acknowledges the significance of this research in changing the treatment landscape for myelofibrosis.
Read more →KPTIKaryopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
Karyopharm Therapeutics has presented preliminary data from the SIENDO study indicating improved overall survival (OS) in patients with advanced or recurrent TP53 wild-type endometrial cancer receiving selinexor. The exploratory subgroup analysis revealed median OS not reached for selinexor-treated patients, suggesting a potential benefit of this treatment. Safety data from the study did not indicate new safety signals, although common adverse events included nausea and thrombocytopenia. The results demonstrate the ongoing need for effective therapies in this area and support further evaluation of selinexor in upcoming pivotal trials.
Read more →KPTIKaryopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
Karyopharm Therapeutics announced several abstracts on selinexor data focused on myelofibrosis will be presented at the upcoming 65th ASH Annual Meeting. The presentations include long-term efficacy results from a Phase 1 study as well as data from a global Phase 3 trial. Company executives expressed confidence in the drug's potential benefits for patients with this disease and reiterated their commitment to addressing unmet medical needs in oncology.
Read more →KPTIKaryopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics reported its third quarter 2023 financial results, achieving total revenue of $36 million, with net product revenue from XPOVIO at $30.2 million. The company maintains its guidance for full-year total revenue between $145 million and $160 million. Notably, strong durability data from a Phase 1 study of Selinexor combined with Ruxolitinib was highlighted, along with a collaboration with Bristol Myers Squibb for advancing treatments in relapsed/refractory multiple myeloma. Despite these achievements, net product revenue showed a decrease compared to the previous year, impacted by competitive pressures in the market.
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO (selinexor)
Karyopharm Therapeutics Inc. reported its third quarter 2023 financial results, with total revenue of $36.0 million, slightly down from the previous year. The company continues to project total revenue for the year between $145 million and $160 million. Notable clinical progress includes durability seen in myelofibrosis patients receiving selinexor. However, the company reported a net loss of $34.5 million for the quarter and observed a decline in net product revenue compared to the previous year.
Read more →KPTIKaryopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Karyopharm Therapeutics has announced a clinical trial collaboration with Bristol Myers Squibb to evaluate the novel CELMoD agent, mezigdomide, in combination with selinexor for patients with relapsed/refractory multiple myeloma. The Phase 1b/2 trial aims to assess the safety and efficacy of this oral regimen in patients who have progressed after prior therapies, specifically those who are ineligible for CAR-T or bispecific antibody treatments. The trial is set to begin in the first half of 2024, marking a significant step towards improving treatment options in this difficult-to-treat population.
Read more →KPTIKaryopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
Karyopharm Therapeutics Inc. will report its third quarter financial results on November 2, 2023. A conference call is scheduled for the same day at 8:00 a.m. ET, where management will discuss the financial results and other updates. Investors can join the call via provided local and international numbers, and a live audio webcast will also be available.
Read more →KPTI▲ +7.1%on this news
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
Karyopharm Therapeutics Inc. announced that several abstracts regarding new data on selinexor will be presented at the upcoming 2023 International Myeloma Society Annual Meeting and the ESGO Congress. Reshma Rangwala, Chief Medical Officer, expressed optimism about the meaningful benefits of selinexor across various cancers. The presentations will include both oral and poster sessions focusing on endometrial cancer and multiple myeloma, demonstrating ongoing research efforts in these areas.
Read more →KPTI▲ +6.3%on this newsshared move
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
Karyopharm Therapeutics has appointed Dr. Zhen Su, an experienced leader in oncology, to its Board of Directors effective August 31, 2023. Dr. Su brings a wealth of knowledge from his previous roles in leading oncology divisions at various pharmaceutical companies. His appointment is expected to provide strategic guidance as Karyopharm aims to expand its product offerings and enhance treatment options for cancer patients. The company is focused on progressing its core programs during this growth phase.
Read more →KPTIKaryopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. reported a total revenue of $37.6 million for the second quarter of 2023, with XPOVIO net product revenue reaching $28.5 million. The company maintained its total revenue guidance for the full year between $145 million and $160 million, while also announcing a workforce reduction of about 20% to improve financial health. Karyopharm has initiated a pivotal Phase 3 study for selinexor in combination with ruxolitinib for myelofibrosis and received Fast Track Designation from the FDA. Recent results from clinical studies show promising trends in the efficacy of selinexor for specific cancer types, including endometrial cancer.
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO (selinexor
Karyopharm Therapeutics reported its financial results for the second quarter of 2023, recording total revenues of $37.6 million. The company highlighted significant developments in its clinical pipeline, particularly the initiation of a Phase 3 study of selinexor for myelofibrosis and receipt of Fast Track Designation from the FDA. Despite these advancements, Karyopharm also noted a net loss of $32.6 million for the quarter, reflecting ongoing challenges in revenue generation. The company maintains its full-year revenue guidance and continues to optimize its operations.
Read more →KPTI▲ +8.8%on this news
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
Karyopharm Therapeutics Inc. is scheduled to report its second quarter 2023 financial results on August 2, 2023. The company will hold a conference call at 8:00 a.m. ET to discuss the results and provide updates. Interested parties can join the call by phone or via a live audio webcast, which will also be archived on the company’s website after the event.
Read more →KPTIKaryopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Karyopharm Therapeutics presented updated findings from the SIENDO study, indicating promising efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer. The exploratory analysis showed a median progression-free survival of 27.4 months for those treated with selinexor compared to just 5.2 months for the placebo group. The ongoing Phase 3 study, XPORT-EC-042, aims to further explore selinexor as a maintenance therapy. Despite some positive results, the broader findings of the SIENDO study did not show clinically meaningful improvements for all patients.
Read more →KPTI▲ +7.4%on this news
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
Karyopharm Therapeutics has announced an updated subgroup analysis of the SIENDO study focusing on patients with TP53 wild-type endometrial cancer. This data will be presented during the American Society of Clinical Oncology (ASCO) Plenary Series on July 25, 2023, reinforcing the company's ongoing Phase 3 study that evaluates selinexor as maintenance therapy. The study aims to determine the efficacy of selinexor following systemic therapy in this patient population. The SIENDO study's findings are intended to support the development of novel cancer therapies.
Read more →KPTIKaryopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
Karyopharm Therapeutics has been granted Fast Track Designation by the FDA for its drug selinexor, aimed at treating myelofibrosis. This designation recognizes the drug's potential to meet the substantial unmet medical needs in this area, which includes various forms of myelofibrosis. A pivotal Phase 3 trial is currently underway to assess its efficacy in combination with ruxolitinib. Promising safety and efficacy data from earlier studies support the drug’s potential impact on treatment approaches.
Read more →KPTIKaryopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
Karyopharm Therapeutics has initiated a pivotal Phase 3 clinical trial (XPORT-MF-034) to evaluate the efficacy and safety of once-weekly selinexor in combination with ruxolitinib for JAKi-naive patients with myelofibrosis. The trial aims to enroll 306 participants and has co-primary endpoints of spleen volume response and symptom improvement at week 24. Preliminary Phase 1 results, showing high response rates in spleen volume reduction and symptom relief, support the trial's rationale. The company plans to present top-line data in 2025, with potential implications for improving treatment outcomes in myelofibrosis.
Read more →KPTIKaryopharm to Participate at the Jefferies Healthcare Conference
Karyopharm Therapeutics Inc. announced its participation in the Jefferies Healthcare Conference, scheduled for June 8, 2023, at 10:00 a.m. ET in New York. The company's senior management team will engage in a fireside chat, offering insights into their operations and future goals. The event will be accessible via a live webcast and later available for replay on Karyopharm's investor website, emphasizing the company's focus on investor engagement.
Read more →KPTIKaryopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
Karyopharm Therapeutics has announced that new data on selinexor will be presented at the upcoming 2023 ASCO and EHA annual meetings. The research focuses on selinexor's role in treating cancers with high unmet needs, including multiple myeloma and endometrial cancer. The company emphasizes the importance of this data in advancing its pipeline and improving patient outcomes in oncology. Key findings will be discussed, showcasing the efficacy and safety of selinexor in various treatment contexts.
Read more →KPTI▼ -24.3%on this news
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. announced its financial results for the first quarter of 2023, reporting total revenues of $38.7 million. Among significant highlights, the company noted promising Phase 1 study results for selinexor in combination with ruxolitinib for treating myelofibrosis, as well as positive interim results for eltanexor in MDS patients. The company also revised its full-year revenue guidance downward due to increased use of patient assistance programs and higher gross-to-net metrics. Despite these challenges, Karyopharm remains optimistic about its pipeline advancements and revenue generation.
Read more →KPTI▼ -24.3%on this news
Targeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO (selinexo
Karyopharm Therapeutics Inc. reported its financial results for the first quarter of 2023, highlighting total revenues of $38.7 million. The net product revenue derived from XPOVIO was $28.3 million, although overall revenue decreased compared to the previous year. The company announced promising results from clinical trials involving selinexor, particularly in myelofibrosis and myelodysplastic neoplasms, and maintained a strong cash position to support its operations. Additionally, Karyopharm revised its revenue expectations for the year, citing increasing pressures from Patient Assistance Programs and reduced licensing revenue.
Read more →KPTIKaryopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
Karyopharm Therapeutics announced interim data from its Phase 2 study of eltanexor for patients with relapsed/refractory higher-risk myelodysplastic neoplasms (MDS). The study reported a median overall survival of 8.7 months and an overall response rate of 27%. Eltanexor was generally well tolerated with manageable adverse effects, yet it remains an investigational drug and lacks regulatory approval. The company highlights the critical need for effective treatments in this difficult-to-treat patient population.
Read more →KPTI▲ +7.5%on this news· ran to -23% by day 3shared move
Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023
Karyopharm Therapeutics Inc. announced that it will report its financial results for the first quarter of 2023 on May 4, 2023. The company will host a conference call and audio webcast at 8:00 a.m. ET to discuss these results and provide additional updates. This move highlights Karyopharm's commitment to transparency and communication with its investors.
Read more →KPTI▼ -9.6%on this news
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023
Karyopharm Therapeutics announced promising results from a Phase 1 trial of selinexor in combination with ruxolitinib for treatment-naive myelofibrosis patients at AACR 2023. The data showed high efficacy rates, with 92% showing spleen volume reduction and 78% experiencing symptom score improvement. Both doses were well tolerated, leading to plans for a pivotal Phase 3 study. Adverse events were noted but were manageable, indicating the therapy's potential as a new standard of care.
Read more →KPTIKaryopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th
Karyopharm Therapeutics Inc. plans to present updated safety and efficacy data from its Phase 1 study of selinexor in combination with ruxolitinib at the AACR Annual Meeting 2023. The presentation will include data from all patients enrolled in the study, highlighting results at 12 and 24 weeks. Additionally, the company will host an investor webcast with a key opinion leader on April 18, 2023, to further discuss the findings and the treatment landscape for myelofibrosis.
Read more →KPTIKaryopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023
Karyopharm Therapeutics announced updates on the Phase 1 study of selinexor in combination with ruxolitinib for treatment-naïve myelofibrosis patients. The results, to be presented at the AACR Annual Meeting 2023, indicate significant reductions in spleen volume and symptom scores, showing positive safety and efficacy profiles. The company is optimistic about the upcoming data presentation and its implications in improving treatment options for patients with myelofibrosis.
Read more →KPTIKaryopharm to Participate at Barclays Global Healthcare Conference
Karyopharm Therapeutics Inc. announced that its senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference, scheduled for March 15, 2023. The event will include a live webcast and accompanying slides, which will be accessible on the company's website for 90 days post-event. This participation reflects Karyopharm's effort to engage with the investment community and share insights on its cancer therapy innovations.
Read more →KPTI▼ -9.9%on this news
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
Karyopharm Therapeutics and Menarini Group have received full marketing authorization from the UK MHRA for NEXPOVIO (selinexor) in combination with bortezomib and dexamethasone. This approval is based on positive outcomes from the Phase 3 BOSTON study, which indicated that the new combination therapy significantly reduces the risk of disease progression compared to standard treatment. Karyopharm's CEO expressed enthusiasm over the expansion of NEXPOVIO's availability for multiple myeloma patients in Great Britain, which also aims to enhance global access to the medication.
Read more →KPTI▲ +10.2%on this newsshared move
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics reported its financial results for Q4 and the full year 2022, highlighting a total revenue of $157.1 million, a decrease from $209.8 million in 2021. Notably, the U.S. XPOVIO net product revenue rose by 22%, reaching $120.4 million. The company provided guidance for 2023, expecting total revenue between $160 million to $175 million. Upcoming clinical milestones in 2023 include interim data releases and the expansion of selinexor's use in cancer therapies.
Read more →KPTI▲ +10.2%on this newsshared move
Targeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress Total Revenue of $157.1 Million and U.S. XPOVIO (selinexor) Net Product
Karyopharm Therapeutics Inc. reported its financial results for the fourth quarter and full year of 2022, indicating significant growth in net product revenue for XPOVIO by 22%. Despite achieving a total revenue of $157.1 million, the company experienced a net loss of $165.3 million for the year, reflecting a reduction from previous earnings. Looking ahead, Karyopharm has provided guidance for 2023, anticipating total revenues between $160 million and $175 million, enabled by a strong cash position extending its financial runway to late 2025.
Read more →KPTIKaryopharm to Present at SVB Securities Global Biopharma Conference
Karyopharm Therapeutics Inc. has announced its participation in the upcoming SVB Securities Global Biopharma Conference, scheduled for February 16, 2023. The company's senior management team will engage in a fireside chat, which will be webcasted live and available for replay for 90 days. This event underscores Karyopharm's position within the biopharma space as it showcases its innovative cancer therapies.
Read more →KPTI▼ -6.8%on this newsshared move
Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
Karyopharm Therapeutics Inc. has announced that it will report its fourth quarter and full year 2022 financial results on February 15, 2023. The company will host a conference call at 8:00 a.m. ET on that date to discuss the financial outcomes and provide further updates about its operations. Investors can access the call via phone or a live audio webcast on the company's website. Karyopharm is recognized for its innovative cancer therapies, particularly XPOVIO® and NEXPOVIO®.
Read more →KPTI▼ -19.1%on this news
Targeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO (
Karyopharm Therapeutics announced preliminary unaudited revenue figures for the fourth quarter and full year of 2022, with total revenue expected to reach approximately $157.7 million. The projected net product revenue for XPOVIO in the U.S. is about $120.4 million, matching company guidance. The company initiated a pivotal Phase 3 study for selinexor as a maintenance therapy in advanced or recurrent endometrial cancer and plans to begin a similar study for frontline myelofibrosis in the first half of 2023. Karyopharm aims to enhance its pipeline and generate value through its ongoing clinical and regulatory efforts.
Read more →KPTI▼ -19.1%on this news
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
Karyopharm Therapeutics Inc. reported preliminary unaudited revenue for the fourth quarter and full year 2022, expecting $157.7 million in total revenue, consistent with company guidance. They're pursuing pivotal Phase 3 studies for their drug selinexor in both advanced endometrial cancer and myelofibrosis, showing a commitment to expanding their pipeline. By collaborating with Foundation Medicine to develop a companion diagnostic, they aim to enhance patient selection. The company also noted solid cash reserves, extending their financial runway to late 2025.
Read more →KPTIKaryopharm to Present at 41st Annual J.P. Morgan Healthcare Conference
Karyopharm Therapeutics Inc. has announced that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The presentation will include a live Q&A session, providing an opportunity for direct interaction with investors. A webcast of the event will be available for replay for 30 days, indicating the company's commitment to transparency and investor communication. This participation underscores Karyopharm's role in the evolving landscape of cancer therapy innovation.
Read more →KPTI▼ -17.9%on this news· ran to -31% by day 3
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
– A 92% SVR35 and a 67% TSS50 were Observed in the Efficacy Evaluable Patients at Week 24 – – 57% of Transfusion Independent Patients Achieved Hemoglobin Stabilization – – Company to Host Investor and Analyst Webcast Featuring Key Opinion Leaders Today at 8:30 a.m. ET – NEWTO
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces $165 Million Private Placement
Karyopharm Announces $165 Million Private Placement NEWTON, Mass. December 5, 2022 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement
Read more →KPTIKaryopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis
– Key Opinion Leaders to Review Highlights from Updated Phase 1 Data to be Presented at ASH 2022 at Company Sponsored Event on Monday, December 12 at 8:30 AM ET – NEWTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmace
Read more →KPTIKaryopharm Announces $165 Million Private Placement
NEWTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with certain institutional investors for
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO (selinexor
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Third Quarter 2021 Initiated Phase
Read more →KPTIKaryopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Third Quarter 2021– – Initiated Phase 3 Study Evaluating Selinexor as a Maintenance Therapy in Women with Advanced or Recurrent
Read more →KPTIKaryopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022
– Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key Efficacy Endpoints of Spleen Volume Reduction, Symptom Improvement, and Hemoglobin Stabilization, with a Generally Manag
Read more →KPTI▼ -6.1%on this newsshared move
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Oct. 31, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical co
Read more →KPTIKaryopharm to Report Third Quarter 2022 Financial Results on November 3, 2022
-- Conference Call Scheduled for Thursday, November 3, 2022, at 4:30 p.m. ET -- NEWTON, Mass., Oct. 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report t
Read more →KPTIKaryopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 2021 – – Received Full Marketing Authorization from the European Commission Expanding Indication fo
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quar
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021; XPOVIO (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 Recei
Read more →KPTI▲ +5.4%on this newsshared move
Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference
NEWTON, Mass., Aug. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 Wedbush
Read more →KPTIKaryopharm to Report Second Quarter 2022 Financial Results on August 4, 2022
-- Conference Call Scheduled for Thursday, August 4, 2022, at 8:00 a.m. ET -- NEWTON, Mass., July 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report sec
Read more →KPTIKaryopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 – NEWTON, Mass. and FLORENCE, Italy, July 21, 2022 /PRNe
Read more →KPTIKaryopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes
– FDA Fast Track Designation and European Commission Orphan Medicinal Product Designation Underscore the Significant Need for New Treatment Options for MDS – NEWTON, Mass., July 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutic
Read more →KPTIKaryopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxicities and 75% of Evaluable Patients Demonstrating ≥35% Spleen Volume Reduction (SVR 35
Read more →KPTIThe European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study
- Phase 3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma - ROTTERDAM, Netherlands and NEWTON, Mass., May 25, 2022 /PRNewswire/ -- The European Myeloma Network
Read more →KPTIKaryopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
̶ European Commission Decision Anticipated within Approximately 60 Days – NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Gro
Read more →KPTIKaryopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
NEWTON, Mass., May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that initial data from a Phase 1 portion of the Ph 1/2 study evaluating selinexor in combination w
Read more →KPTI▲ +14.9%on this newsshared move
Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 RBC Cap
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter
Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners XPOVIO (selinexor) Net Product Revenue of
Read more →KPTIKaryopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – – XPOVIO® (selinexor) Net Product Revenue of $28.3 Million, with a 30% Increase Over Q1 2021 – – Preliminary Data from Phase
Read more →KPTIKaryopharm to Report First Quarter 2022 Financial Results on May 5, 2022
-- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET -- NEWTON, Mass., April 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first
Read more →KPTIKaryopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
NEWTON, Mass., April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts highlighting selinexor clinical research have been selected for presentation,
Read more →KPTIKaryopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference
NEWTON, Mass., April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Canaccord Ge
Read more →KPTI▲ +6.5%on this newsshared move
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer
- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauffman Will Transition Out of the Company on May 31, 2022 - - Dr. Shacham Will
Read more →KPTI▲ +7.2%on this news
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
Study Results to be Presented at the European Society of Medical Oncology's Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on Women's Cancer Company to Host Investor Conference Call on March 17th at 4:30 pm ET NEWTON, Mass., March 16, 2022 /PRNewsw
Read more →KPTIKaryopharm Names New Head of Investor Relations
– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20 Years of Diverse International Experience Across Investor Relations, Business Development, Investment Analysis and Portfoli
Read more →KPTI▲ +10.6%on this newsshared move
Karyopharm to Participate at the Barclays Global Healthcare Conference
NEWTON, Mass., March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Barclays Glo
Read more →KPTIKaryopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
NEWTON, Mass., March 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its previou
Read more →KPTI▼ -28.4%on this news
Karyopharm Announces Changes to Its Clinical Leadership Team
NEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Se
Read more →KPTI▲ +12.2%on this news· ran to +33% by day 3
Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a
Read more →KPTI▼ -20%on this newsshared move
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full yea
Read more →KPTI▼ -20%on this newsshared move
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 Selinexor In ENDOmetrial Cancer (SIENDO/ENGOT-EN5/GOG-3
Read more →KPTI▼ -20%on this newsshared move
Targeting Disease at the Nuclear Pore Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress XPOVIO Achieves Net Product Revenue of $98.4 Million for Full Yea
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company XPOVIO Achieves Net Product Revenue of $98.4 Million for Full Year 2021; Company Provides Full Year 2022 XPOVIO Net Product Revenue Guidance of $135 to $145 Million - of
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022
NEWTON, Mass., Feb. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022. K
Read more →KPTIKaryopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
NEWTON, Mass., Jan. 24, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for eltanexo
Read more →KPTI▲ +7.1%on this newsshared move
Karyopharm to Present at B. Riley Securities Oncology Investor Conference
NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually
Read more →KPTI▲ +9.9%on this news
Targeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives Unaudited Net Product Revenues of Approximately $29.7 M
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for the Full Year 2021 Company
Read more →KPTI▲ +9.9%on this news
Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer
NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer. She will be responsible for lead
Read more →KPTI▲ +9.9%on this news
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives
NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO,
Read more →KPTIKaryopharm to Present at 40th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 4, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present at the 40th
Read more →KPTIKaryopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
NEWTON, Mass. and FLORENCE, Italy, Dec. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, ("Menarini"), a privately-held, leading international pharmaceutical c
Read more →KPTIKaryopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
NEWTON, Mass., Dec. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting updated data from the Phase 2 ESSENTIAL study, an investigator-s
Read more →KPTIKaryopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors
NEWTON, Mass., Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021.
Read more →KPTIKaryopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician
NEWTON, Mass., Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in a new Phase 2 study evaluating oral selinexor, the Company's first-i
Read more →KPTI▲ +8.8%on this newsshared move
Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer
NEWTON, Mass., Dec. 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the completion of patient recruitment in the Phase 3 SIENDO study evaluating the efficacy and safe
Read more →KPTIKaryopharm to Host Virtual Investor Day on December 8, 2021
NEWTON, Mass., Dec. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a virtual Investor Day on Wednesday, December 8, 2021 from 10:00 a.m. to 12:30 p.m. E
Read more →KPTIKaryopharm to Participate at Jefferies London Healthcare Conference
NEWTON, Mass., Nov. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a f
Read more →KPTIKaryopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition
NEWTON, Mass., Nov. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a Phase 2 study evaluating selinexor, a first-in-class, or
Read more →KPTI▲ +37.4%on this newsshared move
Targeting Disease at the Nuclear Pore Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights Third Quarter 2021 XPOVIO (selinexor) Net Product Revenues of $26.7 Million, Up 32% Se
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Quarter 2021 XPOVIO (selinexor) Net Product Revenues of $26.7 Million, Up 32% Sequential Quarter-Over-Quarter and 25% Year-Over-Year Milestone-Driven Q4 with Top-Line Data From Phase 3 SIENDO
Read more →KPTI▲ +37.4%on this newsshared move
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights
NEWTON, Mass., Nov. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2021 and provided business highlights. "Drive
Read more →KPTIKaryopharm to Report Third Quarter 2021 Financial Results on November 3, 2021
NEWTON, Mass., Oct. 27, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021. Karyopha
Read more →KPTIKaryopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome
NEWTON, Mass., Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an ongoing open-label Phase 1/2 study inve
Read more →KPTIKaryopharm Announces Upcoming Virtual Investor Conference Participation
NEWTON, Mass., Sept. 7, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in the following vi
Read more →KPTI▼ -24.2%on this news
Targeting Disease at the Nuclear Pore Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results Achieved Second Quarter 2021 XPOVIO (selinexor) Net Product Revenues of $20.2 Million and $41.9 Milli
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results Achieved Second Quarter 2021 XPOVIO (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First Half of 2020 Forward to a Mile
Read more →KPTI▼ -24.2%on this news
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
NEWTON, Mass., Aug. 5, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended June 30, 2021. Richard Paulson, Pre
Read more →KPTIKaryopharm to Report Second Quarter 2021 Financial Results on August 5, 2021
NEWTON, Mass., July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021. Karyopharm
Read more →KPTIKaryopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis
NEWTON, Mass., July 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evalua
Read more →KPTIKaryopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million
NEWTON, Mass., June 24, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC
Read more →KPTIKaryopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress
NEWTON, Mass., June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual presentation, including one oral presentation,
Read more →KPTIKaryopharm Announces Key Changes to Its Commercial Leadership Team
NEWTON, Mass., June 8, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced key management changes to its commercial organization, including the appointment of Sohanya Cheng,
Read more →KPTIKaryopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets
NEWTON, Mass., June 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for XPOVIO, the Company's first-in-class, oral Selective Inhibitor
Read more →KPTIKaryopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
NEWTON, Mass., June 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on May 26, 2021 the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) granted con
Read more →KPTIKaryopharm kündigt offene Rekrutierung an teilnehmenden Kliniken in Europa für eine Phase-3-Erhaltungsstudie zur Evaluierung von Selinexor bei Patientinnen mit Endometriumkrebs nach Kombinations-Chemotherapie an
NEWTON, Massachusetts, 26. Mai 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), ein pharmazeutisches Unternehmen im kommerziellen Stadium, das Pionierarbeit bei der Entwicklung neuartiger Krebstherapien leistet, gab heute bekannt, dass die Rekrutierung für seine
Read more →KPTIKaryopharm anuncia la apertura de inscripciones para un estudio de fase 3 que evalúa Selinexor
-Karyopharm anuncia la apertura de inscripciones en los hospitales participantes en Europa para un estudio de mantenimiento de fase 3 que evalúa Selinexor en pacientes con cáncer de endometrio tras la quimioterapia combinada NEWTON, Mass., 26 de mayo de 2021 /PRNewswire/ -- Kary
Read more →KPTIKaryopharm annonce l
NEWTON, Massachusetts, 27 mai 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq : KPTI), une société pharmaceutique en phase de commercialisation, pionnière de nouvelles thérapies contre le cancer, a annoncé aujourd'hui que le recrutement pour son étude d'entretien de pha
Read more →KPTIKaryopharm to Participate at Jefferies 2021 Virtual Healthcare Conference
NEWTON, Mass., May 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in a fireside chat a
Read more →KPTIKaryopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
NEWTON, Mass., May 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation
Read more →KPTIKaryopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., May 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021. In addition, Karyopharm highlighted select co
Read more →KPTIKaryopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
NEWTON, Mass., May 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Richard Paulson as Karyopharm's President and Chief Executive Officer, effective
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO (selinexor) Net P
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO (selinexor) Net Product Sales of $21.7 Million Conditional Marketing Authorization Granted by the European Comm
Read more →KPTIKaryopharm to Report First Quarter 2021 Financial Results on May 3, 2021
NEWTON, Mass., April 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report first quarter 2021 financial results on Monday, May 3, 2021. Karyopharm's man
Read more →KPTIKaryopharm Announces European Medicines Agency
NEWTON, Mass., April 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company's Type II Variation Marketing
Read more →KPTIKaryopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
NEWTON, Mass., April 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that health-related quality of life (HRQoL) data from the Phase 3 portion of the SEAL (Selinexor
Read more →KPTIKaryopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
NEWTON, Mass., March 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (s
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress Commercial Launch of XPOVIO (selinexor) In Expanded Multiple Myeloma Ind
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Commercial Launch of XPOVIO (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval XPOVIO Net Product Sales of $20.2 Milli
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020. In addition, Karyop
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 11,
Read more →KPTIKaryopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma
NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval
Read more →KPTIKaryopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has ad
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update Unaudited Total Revenues of between $35.0 Million and $36.0
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 XPOVIO (sel
Read more →KPTIKaryopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
NEWTON, Mass., Jan. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net prod
Read more →KPTIKaryopharm to Present at 39th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 39th Annual J.P. Morga
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces FDA Approval of XPOVIO (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy Oral XPOVIO Now Available as a Treatment Op
Karyopharm Announces FDA Approval of XPOVIO (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands Addres
Read more →KPTIKaryopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor), the Company's
Read more →KPTIKaryopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel. Mr. Mano brings over 1
Read more →KPTIKaryopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN) added three different XPOVIO® (selinexor) c
Read more →KPTIKaryopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting data related to XPOVIO® (selinexor), the Company's first-in-clas
Read more →KPTIKaryopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that over twenty presentations related to XPOVIO® (selinexor), the Company's first-in-class, oral S
Read more →KPTIKaryopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a virtual investor and analyst event to discuss the Company's pipeline of clinica
Read more →KPTIKaryopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointments of Chen Schor, MBA, to its Board of Directors and Stephen Mitchener, PharmD, as C
Read more →KPTIKaryopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modifications
NEWTON, Mass., Nov. 25, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that following a pre-specified interim futility analysis for the ongoing Phase 3 SIENDO study, th
Read more →KPTIKaryopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
NEWTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will present positive results from the Phase 3 portion of the randomized, double blind, placebo
Read more →KPTIKaryopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
NEWTON, Mass., Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON (Bortezomib, Selinexor and Dexamethasone) study evaluating
Read more →KPTIKaryopharm to Participate at Jefferies 2020 Virtual London Healthcare Conference
NEWTON, Mass., Nov. 10, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fires
Read more →KPTIKaryopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twenty-one abstracts have been selected for virtual presentation, including two oral presenta
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma Third Quarter 2020 XPOVIO
Read more →KPTIKaryopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 portion of the randomized, double blind, placebo contro
Read more →KPTIKaryopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2020. In addition, Karyopharm highlighted sel
Read more →KPTIKaryopharm to Report Third Quarter 2020 Financial Results on November 2, 2020
NEWTON, Mass., Oct. 26, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2020 financial results on Monday, November 2, 2020. Karyopharm's
Read more →KPTIKaryopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19
NEWTON, Mass., Oct. 6, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation at the International Society for Influenza and Other Respiratory Virus Diseas
Read more →KPTIKaryopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020
NEWTON, Mass., Sept. 14, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts have been selected for poster presentation at the European Society for Medic
Read more →KPTIKaryopharm Announces September 2020 Virtual Investor Conference Participation
NEWTON, Mass., Sept. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fires
Read more →KPTIKaryopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors
NEWTON, Mass., Aug. 31, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Christy J. Oliger to its Board of Directors. Ms. Oliger is the former Senior V
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress Second Quarter 2020 XPOVIO Net Product Sales of $18.6 Million; Strongest Quarterly Sal
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress Second Quarter 2020 XPOVIO Net Product Sales of $18.6 Million; Strongest Quarterly Sales Since July 2019 Launch XPOVIO Approved by FDA as a New Treatment for Patients with Relapsed
Read more →KPTIKaryopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Aug. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020. In addition, Karyopharm highlighted select c
Read more →KPTIKaryopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
NEWTON, Mass., July 28, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday, August 4, 2020. Karyopharm's management team will host a conf
Read more →KPTIU.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
Karyopharm Therapeutics announced that the FDA has accepted its supplemental New Drug Application for XPOVIO (selinexor) as a treatment for multiple myeloma patients who have undergone at least one prior therapy. A decision from the FDA is expected by the end of Q1 2021. If approved, XPOVIO will provide an important new treatment option for this patient population.
Read more →KPTIKaryopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research
Karyopharm Therapeutics has entered a Cooperative Research and Development Agreement with the National Cancer Institute to advance the research of XPOVIO (selinexor). This partnership aims to explore the safety and efficacy of XPOVIO across various cancer indications, building on previous encouraging results. The collaboration seeks to enhance treatment options for patients with unmet medical needs in oncology.
Read more →KPTIKaryopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)
Karyopharm Therapeutics announced preliminary unaudited net product sales of approximately $18.5 million for XPOVIO in Q2 2020, marking a 15% increase from the previous quarter. This is the strongest sales performance since the drug's launch in July 2019, despite challenges posed by the COVID-19 pandemic. The company also highlighted recent FDA accelerated approval for XPOVIO in treating relapsed or refractory diffuse large B-cell lymphoma.
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO (selinexor) Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the S
Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO (selinexor) Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch NEWTON, Mass. July 14, 2020
Read more →KPTIKaryopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
Karyopharm Therapeutics announced the publication of Phase 2b SADAL study results for XPOVIO (selinexor) in The Lancet Haematology. The study showed a 28% overall response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL). The FDA approved XPOVIO for this indication, highlighting its potential as a new treatment option.
Read more →KPTIKaryopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Karyopharm Therapeutics announced FDA approval for XPOVIO (selinexor) as the first oral therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval follows a pivotal study showing a 29% overall response rate. XPOVIO is now available in the U.S. and will be marketed alongside its existing oncology indication. The company plans to submit a marketing application to the European Medicines Agency in 2021.
Read more →KPTIKaryopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
Karyopharm Therapeutics presented data on XPOVIO (selinexor) and eltanexor at the EHA 2020 Virtual Annual Meeting. Key findings from the Phase 2b SADAL study indicated a median overall survival of 9 months for patients with relapsed or refractory DLBCL, exceeding historical expectations. The company is awaiting FDA decisions on supplemental drug applications for selinexor, which may expand its indications.
Read more →KPTIKaryopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics has initiated dosing for the first patient in a Phase 1/2 clinical trial of selinexor, targeting newly diagnosed or recurrent glioblastoma. The study will evaluate selinexor in combination with standard therapies across multiple treatment arms. Previous studies have shown selinexor's potential efficacy, but the challenges of glioblastoma treatment remain significant.
Read more →KPTIKaryopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
Karyopharm Therapeutics announced positive results from the Phase 3 BOSTON study, demonstrating that the combination of once-weekly XPOVIO, Velcade, and dexamethasone significantly prolonged median progression-free survival by 47% compared to standard treatment. The study also showed superior efficacy and lower rates of peripheral neuropathy. A supplemental New Drug Application has been submitted to the FDA for XPOVIO's approval as a new treatment for multiple myeloma.
Read more →KPTIKaryopharm to Participate at Jefferies Virtual Healthcare Conference
-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Offic
Read more →KPTIKaryopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it will host an investor conference call to discuss
Read more →KPTIKaryopharm Submits Supplemental New Drug Application to FDA for XPOVIO (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval fo
Read more →KPTIKaryopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoi
Read more →KPTIKaryopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
NEWTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Gl
Read more →KPTIKaryopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
-- Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be Submitted by End of May 2020 -- -- First Quarter 2020 XPOVIO Net Product Sales of $16.1 Million
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progre
Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be S
Read more →KPTIKaryopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study - NEWTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharma
Read more →KPTIKaryopharm to Report First Quarter 2020 Financial Results on May 5, 2020
-- Conference Call Scheduled for Tuesday, May 5, 2020, at 8:30 a.m. ET -- NEWTON, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will report first quarter 2020 financial results on Tuesday, May 5, 2020. Karyopharm's m
Read more →KPTIKaryopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
NEWTON, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is e
Read more →KPTIKaryopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
− Company to Initiate a Global Randomized Clinical Trial to Treat Patients with COVID-19 − − XPO1 Inhibitors have Previously Demonstrated Preclinical Activity Against Numerous Respiratory Viruses (Including SARS-CoV) and Associated Inflammation – − BOSTON sNDA Submission on Tar
Read more →KPTIKaryopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 151,200 shares of Karyo
Read more →KPTIKaryopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
NEWTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm’s commercial strat
Read more →KPTIKaryopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
NEWTON, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’
Read more →KPTIKaryopharm Therapeutics Announces Pricing of Public Offering of Common Stock NEWTON, Mass .
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock NEWTON, Mass. March 3, 2020 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the pricing of its previously announced registered underwritten publi
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior
Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy Once-Weekly XPOVIO (selinexor), Once-Weekly Velcade (bortezomib) plus Dexameth
Read more →KPTIKaryopharm Therapeutics Announces Proposed Public Offering of Common Stock
NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Kary
Read more →KPTIKaryopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy
− Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) Regimen − −
Read more →KPTIKaryopharm Appoints Richard Paulson to its Board of Directors
NEWTON, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of Richard Paulson to its Board of Directors. Mr. Paulson is currently Executive Vice President and Chief Execu
Read more →KPTIKaryopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference
NEWTON, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 9th Annual SVB Leerink Glob
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 M
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 XPOVIO Prescription Demand Increased by 65% in Fourth Quarter 2019 Co
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
-- XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 -- -- XPOVIO Prescription Demand Increased by 65% in Fourth Quarter 2019 Compared to Third Quarter 2019 -- -- sNDA for Selinexor in DLBCL Submitted to FDA -- -- Phase 3 BOSTON
Read more →KPTIKaryopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO (Selinexor) in Israel
NEWTON, Mass. and PETAH TIKVA, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group, today announced their entry into an exclusive distribution agreement for
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
NEWTON, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 13, 2020. Karyopharm's management
Read more →KPTIKaryopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 87,000 sh
Read more →KPTIKaryopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO (selinexor) and Provides Commercial Update
-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 -- -- Approximately 1,400 XPOVIO Prescriptions Fulfilled in the U.S. from Launch Through Year End 2019 -- NEWTON, Mass., Jan. 13,
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO (selinexor) and Provides Commercial Update XPOVIO Unaudited Net Product Sales of
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO (selinexor) and Provides Commercial Update XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Ful
Read more →KPTIKaryopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on T
Read more →KPTIKaryopharm Submits New Drug Application to U.S. FDA for XPOVIO (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NEWTON, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for X
Read more →KPTIKaryopharm Presents XPOVIO (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma -- -- All Oral Regimen of Once-We
Read more →KPTIKaryopharm Reports New and Updated XPOVIO (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting
-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst®-Naïve and Revlimid®-Relapsed or -Refractory Myeloma with Progression-Free Survival of 12.2 Months -- -- Selinexor and L
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports New and Updated XPOVIO (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting All Oral Regimen of On
Karyopharm Reports New and Updated XPOVIO (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst and Low Dose Dexamethasone Demonstrates 56% Overall Respons
Read more →KPTIKaryopharm Announces XPOVIO (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Highlighted -- -- Other Key Presentations Include New Data from the S
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine Ac
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine Achieved XPOVIO U.S. Net Product Sales of $12.8 Million with Over 500 Prescriptions Fulfilled as
Read more →KPTIKaryopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO® U.S. Net Product Sales of $12.8 Million with Over 500 Prescriptions Fulfilled as of September 30, 2019 – − Strengthened Balance Sheet with Cash Runway Expected to be Suf
Read more →KPTIKaryopharm to Report Third Quarter 2019 Financial Results on November 4, 2019
NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019 financial results on Monday, November 4, 2019. Karyopharm's management team will host a
Read more →KPTIKARYOPHARM 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
NEW ORLEANS, La., Sept. 22, 2019 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have only until September 23, 2019 to file lead plaint
Read more →KPTIKaryopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150 million to support the ongoing develo
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million Investment Expected to Extend Karyopharm s Cash Runway into Middle of 2021 NEWTON, Ma
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million Investment Expected to Extend Karyopharm s Cash Runway into Middle of 2021 NEWTON, Mass. September 16, 2019 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmace
Read more →KPTIKaryopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop
NEWTON, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for XPOVIO™ (selinexor) will be presented at the 17th International Myeloma Wor
Read more →KPTIKaryopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Bronstein, Gewirtz & Grossman, LLC – Class Action Update
NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below
Read more →KPTIKaryopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences: The Baird 2019 Global Heal
Read more →KPTIKaryopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) – Class Action Reminder – Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below
Read more →KPTIKaryopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine
-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody -- -- In STORM, XPOVIO Achieved a 26% Overall Response Rate, 8.6 Mon
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress - XPOVIO Commercial Launch Underway Following July 3 rd FDA Accelerated Approval - - X
Karyopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress - XPOVIO Commercial Launch Underway Following July 3rd FDA Accelerated Approval - - XPOVIO is the First and Only Prescription Medicine Approved in the U.S. for the Treatment of Pat
Read more →KPTIKaryopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
− XPOVIO™ Commercial Launch Underway Following July 3rd FDA Accelerated Approval − − XPOVIO is the First and Only Prescription Medicine Approved in the U.S. for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory
Read more →KPTIKaryopharm to Report Second Quarter 2019 Financial Results on August 6, 2019
NEWTON, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that it will report second quarter 2019 financial results on Tuesday, August 6, 2019. Karyopharm's management team will host a
Read more →KPTIKaryopharm Therapeutics Shareholder Alert: Kehoe Law Firm, P.C. Investigating Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
PHILADELPHIA, July 25, 2019 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. announces that it is investigating securities claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) to determine whether Karyopharm and certain of its offic
Read more →KPTIKaryopharm Announces FDA Approval of XPOVIO TM (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA XPOVIO is th
Karyopharm Announces FDA Approval of XPOVIOTM (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA XPOVIO is the First and Only Prescription Medicine Approved by the FDA
Read more →KPTIKaryopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Ag
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma Single-Agent Oral Selinexor Induces a 28.3% Overall Response
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Single-Agent Oral Selinexor Induces a 28.3% Overall Response Rate, Including a 10.2% Complete Response Amongst Patients with a Complete or Partial Response, Median Duration of
Read more →KPTIKaryopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
-- Single-Agent Oral Selinexor Induces a 28.3% Overall Response Rate, Including a 10.2% Complete Response Rate -- -- Amongst Patients with a Complete or Partial Response, Median Duration of Response was 9.2 Months -- NEWTON, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Karyopharm T
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting Once Weekly Oral Selinexor in
Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting Once Weekly Oral Selinexor in Combination with Kyprolis and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heav
Read more →KPTIKaryopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting
− Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma – − Once Weekly Oral Selinexor in Combination with Darzalex® and Low Dose Dexamethasone Demonstrates 73
Read more →KPTIKaryopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evalua
Read more →KPTIKaryopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award
NEWTON, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief Scientific Officer, Sharon Shacham, PhD, MBA, for winning the esteemed New York Intellectual Propert
Read more →KPTIKaryopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
-- FDA Extends Review Period for Selinexor New Drug Application to July 6, 2019 -- -- Selinexor MAA Validated in Europe; Approval Decision Expected by End of 2019 -- -- Conference Call Scheduled for Today at 8:30 a.m. ET -- NEWTON, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Karyo
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress FDA Extends Review Period for Selinexor New Drug Application to
Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress FDA Extends Review Period for Selinexor New Drug Application to July 6, 2019 Selinexor MAA Validated in Europe; Approval Decision Expected by End of 2019 Conference Call Scheduled
Read more →KPTIKaryopharm to Report First Quarter 2019 Financial Results on May 9, 2019
-- Conference Call Scheduled for Thursday, May 9, 2019 at 8:30 a.m. ET -- NEWTON, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2019 financial results
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application PDUFA Action Date Extended by Three Months to
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application PDUFA Action Date Extended by Three Months to July 6, 2019 FDA Has Requested Additional Existing Information for Review NEWTON, Mass. March 14, 2019 Karyopharm Therapeutics Inc. (Nasdaq:KPTI
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
-- FDA Advisory Committee Votes 8 to 5 Recommending FDA Wait for the Results from the Ongoing Phase 3 BOSTON Study to Make an Approval Decision for Selinexor -- -- Company Working with FDA to Evaluate Best Path Forward as FDA Completes Its Review of Selinexor NDA; Assigned PDU
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Therapeutics Inc. Consolidated Statements of Operations (in thousands, except share and per share amounts) (Unaudited) For the Quarter Ended, December 31, For the Year End
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update - FDA Advisory Committee Votes 8 to 5 Recommending FDA Wait for the Results from the Ongoing Phase 3 BOSTON Study to Make an Approval Decision for Selinexor - - Company Working
Read more →KPTIKaryopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that NASDAQ has halting trading of the Company’s common stock. The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisor
Read more →KPTIKaryopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the New Drug Application
Read more →KPTIKaryopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer
-- Formerly of Alnylam Pharmaceuticals, Praecis Pharmaceuticals, and KPMG; Brings Over 18 Years of Financial Leadership Experience Within the Life Sciences Industry -- NEWTON, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage p
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
NEWTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. Karyopharm's management te
Read more →KPTIKaryopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
NEWTON, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supp
Read more →KPTIKaryopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
NEWTON, Mass., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for selinexor, the Compan
Read more →KPTIForward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995.
JP Morgan Healthcare Conference January 2019 Targeting Disease at the Nuclear Pore Exhibit 99.1 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of The Private Se
Read more →KPTIKaryopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Mond
Read more →KPTIKaryopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
-- Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in Patients with MR or Better -- -- Once Weekly Oral Selinexor in Combination with Darzalex® and Low Dos
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting 29.6%
Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting 29.6% Overall Response Rate Including 9.6% Complete Response Rate Amongst the Patients with Complet
Read more →KPTIKaryopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
-- 29.6% Overall Response Rate Including 9.6% Complete Response Rate -- -- Amongst the Patients with Complete or Partial Response, Median Duration of Response was 9.2 Months and Median Overall Survival was 29.7 months -- -- Company Plans to Submit New Drug Application to the FD
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress U.S. Food and Drug Administration Accepts Karyopharm s New Drug Application for Selinex
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress U.S. Food and Drug Administration Accepts Karyopharm s New Drug Application for Selinexor and Grants Priority Review; Assigns PDUFA Action Date of April 6, 2019 Fast Track Designatio
Read more →KPTIKaryopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
-- U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review; Assigns PDUFA Action Date of April 6, 2019 -- -- Fast Track Designation Received for Selinexor in Relapsed or Refractory DLBCL; Top-Line Phase 2b SADAL Data i
Read more →KPTIKaryopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, or
Read more →KPTIKaryopharm to Present at the Jefferies 2018 London Healthcare Conference
NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednes
Read more →KPTIKaryopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th
Ceremony to Commemorate Five-Year Listing Anniversary NEWTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, Preside
Read more →KPTIKaryopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
-- Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented -- -- Additional Results from the Pivotal Phase 2b STORM Study in Penta-Refractory Multiple Myeloma and Updated Phase 1b/2 STOMP Data in Relapsed or Refractory Multiple Myeloma to be Highlighted in Oral Pr
Read more →KPTIKaryopharm to Report Third Quarter 2018 Financial Results on November 8, 2018
-- Conference Call Scheduled for Thursday, November 8, 2018 at 8:30 a.m. ET -- NEWTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2018 financial r
Read more →KPTIKaryopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “not
Read more →KPTIKaryopharm Therapeutics Announces Management Change
NEWTON, Mass., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey, Executive Vice President, Chief Financial Officer and Treasurer, intends to leave the company to pursue other i
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes NEWTON, Mass .
Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes NEWTON, Mass. October 11, 2018 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of it
Read more →KPTIKaryopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
NEWTON, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “Notes”). The Notes wi
Read more →KPTIU.S. Food and Drug Administration Accepts Karyopharm s New Drug Application for Selinexor and Grants Priority Review Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta- Refractory
and Drug Administration Accepts Karyopharm s New Drug Application for Selinexor and Grants Priority Review Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta- Refractory Multiple Myeloma PDUFA Date Set for April 6, 2019 NEWTON, Mass.
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes NEWTON, Mass .
Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes Mass. October 9, 2018 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and oth
Read more →KPTIKaryopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes
NEWTON, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior no
Read more →KPTITargeting Disease at the Nuclear Pore Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting Oral Selinexor Achiev
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting Oral Selinexor Achieves 26.2% Overall Response Rate and Duration of Response of 4.4 Months in Overall Study Populati
Read more →KPTIKaryopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors
-- Current Chief Executive Officer of Abeona Therapeutics, Inc. and former Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc.; Brings Wealth of Leadership and Global Strategic Experience -- NEWTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Kar
Read more →KPTIKaryopharm to Present Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma at the Society of Hematologic Oncology 2018 Annual Meeting
-- Oral Selinexor Achieves 25.4% Overall Response Rate and DOR of 4.4 Months in Overall Study Population -- -- Median Survival of 8.6 Months in All Patients; Median Survival of Responders not yet Reached -- -- New Drug Application Submitted to FDA; On Track to Submit MAA in Q1
Read more →KPTIKaryopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress
-- Completed Rolling Submission of a New Drug Application to FDA Seeking Accelerated Approval for Selinexor As a New Treatment for Patients with Penta-Refractory Multiple Myeloma -- -- On Track to Report Top-Line Phase 2b SADAL Data in DLBCL and Complete Enrollment in the Pivota
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma Company to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Recent Bus
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress Completed Rolling Submission of a New Drug Application to FDA Seeking Accelerated Approval for
Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress Completed Rolling Submission of a New Drug Application to FDA Seeking Accelerated Approval for Selinexor As a New Treatment for Patients with Penta-Refractory Multiple Myeloma On Track to R
Read more →KPTIKaryopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
-- Company to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Recent Business Developments on Tuesday, August 7, 2018 at 8:30 a.m. ET -- NEWTON, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharm
Read more →KPTIKaryopharm to Report Second Quarter 2018 Financial Results on August 7, 2018
− Conference Call Scheduled for Tuesday, August 7, 2018 at 8:30 a.m. ET − NEWTON, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2018 financial resul
Read more →KPTIKaryopharm Appoints Ian Karp as Vice President, Investor and Public Relations
-- Formerly of Shire, MedImmune, Centocor and Pharmacia; Brings Over 20 Years of Healthcare Industry Leadership Experience -- NEWTON, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced th
Read more →KPTIKaryopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
-- Company Plans to Complete Submission During the Second Half of 2018 -- NEWTON, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Company has initiated a rolling submission of
Read more →KPTIKaryopharm Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Anand Varadan as Executive Vice President, Chief Commercial Officer. In this role, Mr. Varadan will lead Karyop
Read more →KPTIForward-looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements
Corporate Presentation June 2018 Targeting Disease at the Nuclear Pore Exhibit 99.1 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995. Such
Read more →KPTIKaryopharm Presents Updated Selinexor Phase 1b/2 STOMP Myeloma Data from Multiple Combinations at the European Hematology Association 2018 Annual Meeting
-- SVd Once Weekly Demonstrates 17.8-month PFS and 83% ORR in the BOSTON Multiple Myeloma (MM) Population; 63% ORR in the Overall Study Population -- -- SDd Once Weekly Shows 82% ORR in Patients with Heavily Pretreated Darzalex-Naïve MM; 68% ORR in the Overall Study Population -
Read more →KPTITargeting Disease at the Nuclear Pore Corporate Presentation June 2018 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of The Private Secu
Targeting Disease at the Nuclear Pore Corporate Presentation Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Such forward-looking stateme
Read more →KPTIKaryopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting
Treatment with Selinexor Prolongs Progression-Free Survival Compared to Placebo (5.5 months versus 2.7 months, respectively) in Patients with Liposarcoma Additional Selinexor Data Posters from Investigator-Sponsored Trials Show Early Signals of Activity and Good Tolerability in
Read more →KPTIKaryopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia - Antengene Rights Include All Human Oncology Indica
Karyopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia - Antengene Rights Include All Human Oncology Indications for Selinexor, Eltanexor and KPT-9274, and Non-Onco
Read more →KPTIKaryopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting
NEWTON, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data from the ongoing Phase 1b/2 STOMP study will be presented at the upcoming European He
Read more →KPTIKaryopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting
NEWTON, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2018 Annual Meeting taking place J
Read more →KPTIKaryopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress
-- Oral selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Myeloma -- -- Completed $155.3 Million Public Equity Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares --
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress Oral selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Mont
Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress Oral selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Completed $155.3 Million Public Equity Offering, Including
Read more →KPTIKaryopharm to Report First Quarter 2018 Financial Results on May 10, 2018
NEWTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2018 financial results on Thursday, May 10, 2018. Karyopharm's management team will host a confer
Read more →KPTIKaryopharm Therapeutics Announces Pricing of Public Offering of Common Stock
NEWTON, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 9,152,543 shares of its common stock at a price
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock NEWTON, Mass .
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock NEWTON, Mass. May 2, 2018 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of its previously announced registered underwritten public off
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Oral Selinexor Achieves 25.4% Overall Re
Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Oral Selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory My
Read more →KPTIKaryopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma
- Oral Selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Myeloma - - Company Plans to Submit a New Drug Application to the FDA in the Second Half of 2018 - - Selinexor Continues to Demonstrate a Predic
Read more →KPTIKaryopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
NEWTON, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead, oral Selective Inhibit
Read more →KPTIKaryopharm to Present Preclinical Data at the American Association for Cancer Research 2018 Annual Meeting
Five Posters Highlighting Selinexor Data, Including in Combinations with Zejula® (niraparib) in Ovarian Cancer and Velcade® (bortezomib) in Neuroblastoma Two Posters Featuring Eltanexor Data in Prostate Cancer and AML; One Poster with KPT-9274 Data in Pancreatic Cancer NEWTON,
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
− Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 – − Company Executes Two High-Value Strategic Transactions Providing Substantial Validation for Its Lead Assets and XPO1 Inhibition –
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress - Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory My
Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress - Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 - Company Executes Two High-Val
Read more →KPTIKaryopharm to Report Fourth Quarter and Year End 2017 Financial Results on March 15, 2018
NEWTON, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year end 2017 financial results on Thursday, March 15, 2018. Karyopharm's management team
Read more →KPTIKaryopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions Biogen Brings Expertise in Development and Commercialization of Products for Neurological an
Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions Biogen Brings Expertise in Development and Commercialization of Products for Neurological and Neurodegenerative Diseases Total Deal Valued at Up To
Read more →KPTIth Annual J.P. Morgan Healthcare Conference January 8-11, 2018 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of The Private Securities L
Targeting Disease at the Nuclear Pore Exhibit 99.1 6th Annual J.P. Morgan Healthcare Conference January 8-11, 2018 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litiga
Read more →KPTIKaryopharm Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wedn
Read more →KPTIKaryopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting
− Data Provide Further Evidence of Tolerability with Robust Anti-Myeloma Activity When Selinexor is Combined with Velcade, Pomalyst, Revlimid or Darzalex – − SVd Arm Continues to Show High Response Rates, Including 83% ORR and >13-month PFS in BOSTON Patient Population; 63% ORR
Read more →KPTIKaryopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting
− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma – − Expanding Program to Include Colorectal Cancer, Castration-resistant Prostate Cancer, and Myelodysplastic Syndrome – NEWTON, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting Data Provide Further Evidence of Tolerability wi
Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting Data Provide Further Evidence of Tolerability with Robust Anti-Myeloma Activity When Selinexor is Combined with Velcade, Pomalyst, Revlimid or
Read more →KPTIKaryopharm Therapeutics to Present at the Jefferies 2017 London Healthcare Conference
NEWTON, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conference on Thursd
Read more →KPTIKaryopharm Therapeutics to Participate in the Credit Suisse 26th Annual Healthcare Conference
NEWTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Credit Suisse 26th Annual Healthcare Conference on We
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties w
Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties with Ono Pharmaceutical Co. Ltd. for Selinexor and KPT-8602 In Japan and Certain Other Countries
Read more →KPTIKaryopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
− Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties with Ono Pharmaceutical Co. Ltd. for Selinexor and KPT-8602 In Japan and Certain Other Countries in Asia – − Michael Falvey Named Chief Financial Officer– − Fourteen Abstracts Select
Read more →KPTIKaryopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting
NEWTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 14 abstracts have been selected for presentation, including three oral presentations, at the upcoming American Society of Hem
Read more →KPTIKaryopharm to Report Third Quarter 2017 Financial Results on November 2, 2017
NEWTON, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2017 financial results on Thursday, November 2, 2017. Karyopharm's management team will host a c
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia ONO Rights Includ
Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries Kar
Read more →KPTIKaryopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia
− ONO Rights Include Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries – − Karyopharm to Receive ¥2.5 billion (US$22.3 Million) Upfront; Total Deal Value up to Approximately US$193.0 million with Karyopharm Eligible to R
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma Th
Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of
Read more →KPTIKaryopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
– The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death – – Phase 3 Portion of Study Commenced; Expanded to Include North America and Europe and Expected
Read more →KPTIKaryopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
– Michael Falvey, Formerly an Executive at Millennium Pharmaceuticals, Seven Bridges Genomics, Ahura Scientific, and Aspect Medical Systems, Brings 35 Years of Financial and Operational Experience at High Growth Companies – – Jatin Shah, MD, Formerly Associate Professor and Dire
Read more →KPTIKaryopharm Announces Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
Top-line Phase 1 Selinexor Data in Combination with Chemotherapy Show Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers Top-line Phase 1 KPT-9274 Data Show a Manageable Safety Profile and Early Signals of Anti-Tumor Activity NEWTON, Mass., Sept. 08, 20
Read more →KPTIKaryopharm Therapeutics to Participate in Upcoming Investor Conferences
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The Bai
Read more →KPTIKaryopharm Announces the Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting, taking place September 8
Read more →KPTIKaryopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
− Pivotal Phase 3 BOSTON Study Underway – − Updated Phase 1b/2 STOMP Data Expected by Year End 2017; Top-line Phase 2b STORM Data Expected by April 2018 – − Phase 2 SEAL Hazard Ratio Expected in September/October 2017, Along with Other Pipeline Program Updates During the Second
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress Pivotal Phase 3 BOSTON Study Underway Updated Phase 1b/2 STOMP Data Expected by Year End 2017;
Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress Pivotal Phase 3 BOSTON Study Underway Updated Phase 1b/2 STOMP Data Expected by Year End 2017; Top-line Phase 2b STORM Data Expected by April 2018 Phase 2 SEAL Hazard Ratio Expected in Sep
Read more →KPTIKaryopharm to Report Second Quarter 2017 Financial Results on August 8, 2017
NEWTON, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2017 financial results and provide a company update on Tuesday, August 8, 2017. Karyopharm's ma
Read more →KPTIKaryopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting
Objective Response Rate Increases to 33.3% Overall and is 35% in Patients with “Double- or Triple-Hit” DLBCL With Additional Responders, Median Duration of Response Remains Greater than 7 Months Top-Line Data from SADAL Study Expected in the Second Half of 2018 NEWTON, Mass.,
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting Objective Response Rate Incre
Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting Response Rate Increases to 33.3% Overall and is 35% in Patients with Double- or Triple-Hit DLBCL With Additional Responders,
Read more →KPTIKaryopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
NEWTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in its pivotal Phase 3 study, named the BOSTON (Bortezomib, Selinexor and dexamethasone) study, which
Read more →KPTIKaryopharm’s Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting
NEWTON, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that interim clinical data from the ongoing Phase 2b SADAL study evaluating lead product candidate, selinexor (KPT-330), an oral Se
Read more →KPTIKaryopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress
− Pivotal Phase 3 BOSTON Study Expected to Commence in May 2017 – − Secured $52.2 Million Through Recent Equity Financing and ATM Facility – − Conference Call Scheduled for Today at 8:30 a.m. ET − NEWTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Na
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress Pivotal Phase 3 BOSTON Study Expected to Commence in May 2017 Secured $52.2 Million Through Rec
Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress Pivotal Phase 3 BOSTON Study Expected to Commence in May 2017 Secured $52.2 Million Through Recent Equity Financing and ATM Facility Conference Call Scheduled for Today at 8:30 a.m. ET NEWT
Read more →KPTIKaryopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals – − Karyopharm to Receive $1 Million Upfront Payment, Then Eligible to Receive Up To $43.5 Million in Future Milestones, Plus Royalties – NEWTON, Mass., May 03, 2017 (GLOBE N
Read more →KPTIKaryopharm to Report First Quarter 2017 Financial Results on May 4, 2017
NEWTON, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2017 financial results and provide a company update on Thursday, May 4, 2017. Karyopharm's mana
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock NEWTON, Mass .
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock NEWTON, Mass. April 24, 2017 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that it is commencing a registered underwritten public offering of $40 m
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting Selinexor Achieves Robust and Prolonged Response Rates in Patients
Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting Selinexor Achieves Robust and Prolonged Response Rates in Patients with Relapsed or Refractory DLBCL, Including Against Both GCB and Non-GCB Subtypes 28.6% Overa
Read more →KPTIKaryopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting
Selinexor Achieves Robust and Prolonged Response Rates in Patients with Relapsed or Refractory DLBCL, Including Against Both GCB and Non-GCB Subtypes 28.6% Overall Response Rate Demonstrated with a Median Duration of Greater than Seven Months Top-Line Data from SADAL Study Expe
Read more →KPTIKaryopharm Announces Management Change
NEWTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President, Chief Financial Officer and Treasurer, has stepped down in order to pursue other oppo
Read more →KPTIKaryopharm to Present Selinexor Phase 2b SADAL Data at the American Association for Cancer Research Annual Meeting 2017
Abstract Published Today Highlighting Interim Phase 2b SADAL Results in Patients with Relapsed or Refractory DLBCL Overall Response Rate Greater Than 28%, along with Additional Updated Data, to Be Presented in a Late-Breaking Poster at the Meeting NEWTON, Mass., March 31, 2017
Read more →KPTIKaryopharm to Present at the 16th Annual Needham Healthcare Conference
NEWTON, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference in New Yor
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Update Overall Response Rate of 28.4% Observed in Phase 2b SADAL Study in Relap
Karyopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Overall Response Rate of 28.4% Observed in Phase 2b SADAL Study in Relapsed/Refractory DLBCL; Additional Top-line Data to be Presented as a Late-Breaker at AACR 2017 Annual Me
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Update
− Overall Response Rate of 28.4% Observed in Phase 2b SADAL Study in Relapsed/Refractory DLBCL; Additional Top-line Data to be Presented as a Late-Breaker at AACR 2017 Annual Meeting – − Company Announces FDA-Affirmed Development Path for Selinexor in DLBCL with Potential for Ac
Read more →KPTIKaryopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials
All Currently Enrolled Patients with Stable Disease or Better Can Continue Receiving Selinexor Company Has Amended Investigator’s Brochure and Informed Consent Documents as Requested by FDA Company Expects Timelines for Both Ongoing and Planned Studies to Remain Materially Unch
Read more →KPTIKaryopharm to Report Fourth Quarter and Year End 2016 Financial Results on March 16, 2017
NEWTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year end 2016 financial results and provide a company update on Thursday, March 16, 2017.
Read more →KPTIKaryopharm Announces Results from Interim Analysis of Phase 2 SOPRA Study Evaluating Selinexor in Relapsed/Refractory Acute Myeloid Leukemia
Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation; Patients Deriving Benefit to Remain on Study Clinical Development Continuing in Promising Induction and Combinati
Read more →KPTIKaryopharm Announces the Presentation of New Data at the 2017 American Association for Cancer Research Annual Meeting
Late-Breaking Presentation Highlighting Interim Phase 2b Selinexor Data in Patients with Relapsed or Refractory DLBCL (SADAL Study) Presentations Include Eleven Preclinical Abstracts Describing Key Scientific Findings across the Company’s Oncology Programs Overview of Key Selin
Read more →KPTICorporate Presentation January 2017 KARYOPHARM THERAPEUTICS INC. Targetting Disease at the Nuclear Pore Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harb
Corporate Presentation January 2017 KARYOPHARM THERAPEUTICS INC. Targetting Disease at the Nuclear Pore Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform
Read more →KPTIKaryopharm to Present at the 35th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San
Read more →KPTIKaryopharm and Collaborators Awarded Grant for ALS Research
- Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS - - Fifth Grant Awarded in Support of KPT-350 as a Potential ALS Treatment Option - NEWTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharm
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting - Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patient
Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma - Company to Host Dinner Reception and Webcast Event with Intera
Read more →KPTIKaryopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting
- STOMP Data Continues to Demonstrate High Response Rates in Patients with Heavily Pretreated Multiple Myeloma When Selinexor Is Combined with Bortezomib and Pomalidomide - - Company to Host Dinner Reception and Webcast Event with Interactive Expert Panel Discussion on Monday, D
Read more →KPTIKaryopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting
- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma - - Company to Host Dinner Reception and Webcast Event with Interactive Expert Panel Discussion on Monday, December 5, 2016 at 8:15 p.m. PT - NEWTON
Read more →KPTIKaryopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting
- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia - NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutic
Read more →KPTIKaryopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
NEWTON, Mass. and NORWALK, Conn., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, together with the Multiple Myeloma Research Foundation (MMRF), the leading provider of multiple myeloma research, today announc
Read more →KPTIKaryopharm to Present at the Jefferies 2016 London Healthcare Conference
NEWTON, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Thursd
Read more →KPTIKaryopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress
− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout – − Updated Clinical Data from STORM and STOMP Studies to be Reported in Oral Presentations at ASH 2016; Results Continue to Suppo
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway
Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Updated Clinical Data from STORM and STOMP Studies to be
Read more →KPTIKaryopharm Therapeutics Inc. (Nasdaq: KPTI) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Michael G. Kauffman, M.D., Ph.D., Director, and Chief Executive Officer,
Read more →KPTIKaryopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting
- Diverse Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma - - Twenty-one Abstracts Selected, Including Nine Oral Presentations - NEWTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeut
Read more →KPTIKaryopharm to Ring the Nasdaq Stock Market Closing Bell
NEWTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief Scientific Officer and cofounder Michael G
Read more →KPTIKaryopharm to Report Third Quarter 2016 Financial Results on November 7, 2016
NEWTON, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2016 financial results and provide a company update on Monday, November 7, 2016. Karyopharm's ma
Read more →KPTIKaryopharm to Present at the 15th Annual BIO Investor Forum
NEWTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Executive Vice President, Chief Financial Officer, and Treasurer, will present at the 15th Annual BIO Investo
Read more →KPTIKaryopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting
- Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers - - 49% Disease Control Rate Observed in Ovarian Cancer and 45% Observed in Endometrial Cancer – - Compelling Biomarker Data for Sel
Read more →KPTIKaryopharm Publishes Preclinical Data in Nature Demonstrating Selinexor’s Potential in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Nuclear Transport Machinery Identified as a Necessary and Universal Driver of KRAS-mutant Cell Survival - - Inhibition of the Nuclear Export Protein XPO1 Promoted Apoptosis across a Panel of Aggressive NSCLCs - NEWTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Karyopharm Ther
Read more →KPTIKaryopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication
- XPO1 Inhibition Significantly Reduced Tumor Burden in Platinum Sensitive and Resistant Ovarian Cancer Models- - Company to Report Updated Phase 2 SIGN Data of Selinexor in Gynecological Malignancies at ESMO 2016 - NEWTON, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm T
Read more →KPTIKaryopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD, FCAP, as Senior Vice President, Clinical Development. Dr. Gardner will be responsibl
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma - Selinexor Achieves Promising Response Rates i
Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma - Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refract
Read more →KPTIKaryopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma
- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease - - Expanding Phase 2b STORM Study to Include Approximately 120 Additional Patients with Penta-Refractory Myeloma to Support
Read more →KPTIKaryopharm to Host Conference Call with Update on Multiple Myeloma Plans
NEWTON, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line results from its Phase 2b STORM study and the planned development path for selinexor (KPT-
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress - Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma - - On
Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress - Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma - - On Track to Report Top-Line Data from STORM and STOMP Studies in Relapsed/Refractory Multiple Myel
Read more →KPTIKaryopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma On Track to Report Top-Line Data from STORM and STOMP Studies in Relapsed/Refractory Multiple Myeloma and Updated Data from SIGN Study in Gynecologic Malignancies Conference Call Scheduled for
Read more →KPTIKaryopharm to Present at Upcoming Investor Conferences
NEWTON, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will present at the following upcoming investor conferences: Canaccord Genuity Growth Confere
Read more →KPTIKaryopharm to Report Second Quarter 2016 Financial Results on August 4, 2016
NEWTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016 financial results and provide a company update on Thursday, August 4, 2016. Karyopharm’s m
Read more →KPTIKaryopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting
- Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers - - Posters Highlighting Predictive Biomarkers of Selinexor Activity in Preclinical Models of Gynecological and Colorectal Cancers - NEWTON, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therape
Read more →KPTIKaryopharm Announces Phase 1b Selinexor Sarcoma Data Published in Journal of Clinical Oncology
Data Provide Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose Company Also Announces Orphan Drug Designation Granted by FDA for Selinexor in Soft Tissue Sarcoma NEWTON, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics
Read more →KPTIKaryopharm to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
NEWTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Read more →KPTIKaryopharm Initiates Phase 1 Clinical Trial with KPT-9274
NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1 clinical trial evaluating KPT-9274, an oral, first-in-class, dual-acting p21-activated ki
Read more →KPTIKaryopharm Outlines Key Selinexor Clinical Development Achievements
- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma - - Patient Dosing Underway in Phase 1b Clinical Trial of Selinexor in Combination with Chemotherapeutic, Targeted and Immunotherapeutic Agents - NEWTON, Mass., June 16, 2016 (GLOBE NEWSWIRE) -- Karyopha
Read more →KPTIKaryopharm to Present at the 2016 JMP Securities Life Science Conference
NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on W
Read more →KPTIKaryopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma - - Preclinical Data for Second-Generation SINE™ Compound, KPT-8602, Also Featured - NEWTON, Mass., June 10, 2016 (GLOB
Read more →KPTIKaryopharm to Present at the Jefferies 2016 Healthcare Conference
NEWTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conf
Read more →KPTIKaryopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
NEWTON, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of selinexor (KPT-330) and dexamethasone in combination with bortezomib (Velcade®)
Read more →KPTIKaryopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
NEWTON, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), the Company’s lead product candidate selinexor in development for hematological
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma First-in-Hu
Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma First-in-Human Study Initiated with Second-Generation SINE Compound KPT-8602 in Multiple Myeloma Phase 2 C
Read more →KPTIKaryopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma First-in-Human Study Initiated with Second-Generation SINE™ Compound KPT-8602 in Multiple Myeloma Phase 2 Clinical Data in Multiple Myeloma Expected Mid-Year Conference Call Scheduled for Today
Read more →KPTIKaryopharm to Report First Quarter 2016 Financial Results on May 9, 2016
NEWTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm’s manageme
Read more →KPTIKaryopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
NEWTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of its Selective Inhibitor of Nuclear Export (SINETM) compound, KPT-350, in rodent mo
Read more →KPTIKaryopharm to Present at the 15th Annual Needham Healthcare Conference
NEWTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15th Annual Ne
Read more →KPTIKaryopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus
NEWTON, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has been awarded a grant from the National Institute of Allergy and Infectious Disease (NIAID) to advance development of
Read more →KPTIKaryopharm to Present Data on Oncology Pipeline at the 2016 American Association for Cancer Research Annual Meeting
Two Late-Breaking Posters Featuring the Company’s Lead Drug Candidate, Selinexor (KPT-330), and Second Generation SINE Compound KPT-8602 Seventeen Additional Poster Presentations Highlighting Key Scientific Findings for Selinexor and the Company’s Earlier Stage Oncology Programs
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress Company Continues to Expand its Leadership in SINE TM -based Therapies with Seli
Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress Company Continues to Expand its Leadership in SINETM-based Therapies with Selinexor Clinical Advancement and Presentations of Encouraging Data for Earlier Stage Pipeline Progra
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress
Company Continues to Expand its Leadership in SINETM-based Therapies with Selinexor Clinical Advancement and Presentations of Encouraging Data for Earlier Stage Pipeline Programs Cash Expected to Fund Current R&D Plans into 2018 Several Data Readouts Expected over the Next 18 M
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2015 Financial Results on March 14, 2016
NEWTON, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2015 financial results and provide a company update on Monday, March 14, 2016. K
Read more →KPTIKaryopharm’s Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology
NEWTON, Mass., March 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the publication of results from a Phase 1 clinical trial of selinexor in patients with advanced solid tumors in the Journal of Cl
Read more →KPTIKaryopharm to Present at the Leerink Partners 5th Annual Global Healthcare Conference
NEWTON, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming Leerink Partner
Read more →KPTIKaryopharm Initiates Second Generation SINE™ Compound Clinical Trial in Multiple Myeloma
NEWTON, Mass., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the initiation of a Phase 1/2 study of oral KPT-8602, a novel, second generation, small-molecule selective inhibitor of nuclear ex
Read more →KPTIKaryopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma
NEWTON, Mass., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the initiation of Selinexor in Advanced Liposarcoma (“SEAL”), a new Phase 2/3 clinical trial with oral selinexor, the Company’s fi
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma - Phase 2/3 SEAL Trial Initiated with Oral Selinexor in Patients with Dedifferentiated Liposarcoma Based
Karyopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma - Phase 2/3 SEAL Trial Initiated with Oral Selinexor in Patients with Dedifferentiated Liposarcoma Based on Promising Clinical Data Presented at ASCO 2015 Meeting - Newton, Mass. January 14, 2016 Kar
Read more →KPTIKaryopharm to Present at the 34th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming J.P. Morgan 34t
Read more →KPTIKaryopharm Therapeutics Presents Positive Clinical Data on the Activity of Selinexor in Combination with Other Anticancer Agents across Multiple Hematologic Malignancies at the 2015 American Society of Hematology (ASH) A
Karyopharm Therapeutics Presents Positive Clinical Data on the Activity of Selinexor in Combination with Other Anticancer Agents across Multiple Hematologic Malignancies at the 2015 American Society of Hematology (ASH) Annual Meeting - Selinexor Demonstrates Promising Activity
Read more →KPTIKaryopharm to Present Clinical Data Update for Selinexor (KPT-330) in Hematologic Malignancies
NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of clinical data for its lead drug candidate, selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of
Read more →KPTIKaryopharm Therapeutics, Inc. Forward looking Statements This presentation contains forward looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Unl
Selinexor is a novel, oral selective inhibitor of XPO1 mediated nuclear export with broad single agent anti cancer activity Karyopharm wholly owns the worldwide rights to selinexor with patent protection through at least 2032 Three ongoing later phase studies (SOPRA, SADAL and SI
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Third Quarter 2015 Financial Results and Highlights Recent Progress Robust Recruitment and New Study Initiations Continue Additional Encouraging Data on Selinexor
Karyopharm Reports Third Quarter 2015 Financial Results and Highlights Recent Progress Robust Recruitment and New Study Initiations Continue Additional Encouraging Data on Selinexor in Combination with Other Active Agents to be Presented at ASH Conference Call Scheduled for To
Read more →KPTIKaryopharm Reports Third Quarter 2015 Financial Results and Highlights Recent Progress
- Robust Recruitment and New Study Initiations Continue - - Additional Encouraging Data on Selinexor in Combination with Other Active Agents to be Presented at ASH - Conference Call Scheduled for Today at 8:30 a.m. ET NEWTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Karyopharm
Read more →KPTIKaryopharm to Present Data on Oncology Pipeline at American Society of Hematology 2015 Annual Meeting
NEWTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 17 abstracts, including 5 oral presentations and 12 posters describing the activity of its oncology pipeline for the treatment
Read more →KPTIKaryopharm to Report Third Quarter 2015 Financial Results on November 9, 2015
NEWTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2015 financial results on Monday, November 9, 2015. Karyopharm's management team will host a conf
Read more →KPTIKaryopharm Initiates STOMP Clinical Trial of Oral Selinexor in Multiple Myeloma
NEWTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the initiation of the Selinexor and Backbone Treatments of Multiple Myeloma Patients, (STOMP) study. STOMP is a multi-center, Phas
Read more →KPTIKaryopharm Advancing Neuroprotective SINE(TM) Compounds in Amyotrophic Lateral Sclerosis (ALS)
- Preclinical efficacy of SINE compounds validated in journal Nature publication - - Presentations of ALS abstracts at upcoming AAN and SfN meetings - - Collaborator grant funding supports Karyopharm's ALS research - NEWTON, Mass., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Karyopharm
Read more →KPTIKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
- Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides Update to Certain Trials based on Expanding Clinical Experience - Conference Call Scheduled for today at 8:30 a.m. ET NEWTON, Mass., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Karyopharm
Read more →KPTINASDAQ: KPTI Corporate Presentation August 2015 Targeting Disease at the Nuclear Pore Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of T
Corporate Presentation Targeting Disease at the Nuclear Pore Forward-looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Such forward-looking statements include those re
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers Provides
Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers Provides Update to Certain Trials based on Expanding Clinical Experience Conference Call Scheduled for t
Read more →KPTIKaryopharm to Report Second Quarter 2015 Financial Results on August 10, 2015
NEWTON, Mass., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2015 financial results on Monday, August 10, 2015. Karyopharm's management team will host a conf
Read more →KPTIKaryopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at International Conference on Malignant Lymphoma
NEWTON, Mass., June 22, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical and preclinical data for its lead product candidate, selinexor (KPT-330), a first-in-class,
Read more →KPTIKaryopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting
NEWTON, Mass., June 15, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its lead product candidate, selinexor (KPT-330), a first-in-class, oral Selective I
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting - Clinical Data Highlights Durable Responses Correlatin
Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting - Clinical Data Highlights Durable Responses Correlating with Overall and Progression Free Survival with Single-Agent Selinexor (KPT-330) in Heavily P
Read more →KPTIKaryopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Recurrent Glioblastoma and Advanced Sarcomas at 2015 ASCO Annual Meeting
NEWTON, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its lead product candidate, Selinexor (KPT-330), a first-in-class, oral Selective In
Read more →KPTIKaryopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Heavily Pretreated Gynecological Cancers and Asian Patients With Advanced Malignancies at 2015 ASCO Annual Meeting
NEWTON, Mass., May 30, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its lead product candidate, Selinexor (KPT-330), a first-in-class, oral Selective In
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients with Heavily Pretreated Gynecological Cancers and Asian Patients with Advanced Malignancies at 2015 ASCO Annual
Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients with Heavily Pretreated Gynecological Cancers and Asian Patients with Advanced Malignancies at 2015 ASCO Annual Meeting - Single-Agent Selinexor Demonstrates Durable Anti-tumor Activity or Disease Control ac
Read more →KPTIKaryopharm Initiates STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma
NEWTON, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma). STORM is a multi-center, single-arm Phase 2 study of
Read more →KPTIKaryopharm to Present Clinical Data Update for Selinexor (KPT-330) in Solid Tumors
- Presentation to Include Discussion of Selinexor as Single-Agent in Solid Tumor Malignancies Including Gynecologic Cancers, Recurrent Glioblastoma and Advanced Sarcomas - - Webcast Event Scheduled for Monday, June 1, 2015 at 6:00 p.m. CT - NEWTON, Mass., May 27, 2015 (GLOBE NE
Read more →KPTIKaryopharm to Present Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting
- Presentations Include Clinical Data on Activity of Selinexor (KPT-330) in Diffuse Large B-cell Lymphoma and Acute Myeloid Leukemia - - An Oral Presentation to Highlight the Durability of Responses to Single-Agent Selinexor in DLBCL and a Late-Breaking Poster to Describe Respon
Read more →KPTIKaryopharm to Present Solid Tumor Data on Lead Drug Candidate Selinexor at 2015 American Society of Clinical Oncology Annual Meeting
NEWTON, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four abstracts describing the activity of selinexor (KPT-330), the company's lead drug candidate in development for hematologi
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports First Quarter 2015 Financial Results and Highlights Recent Progress Positive Data in Difficult to Treat Cancers with Significant Unmet Need Further Supports Broad
Karyopharm Reports First Quarter 2015 Financial Results and Highlights Recent Progress Positive Data in Difficult to Treat Cancers with Significant Unmet Need Further Supports Broad Clinical Development Campaign for Selinexor Conference Call Scheduled for today at 8:30 a.m. ET
Read more →KPTIKaryopharm Reports First Quarter 2015 Financial Results and Highlights Recent Progress
Positive Data in Difficult to Treat Cancers With Significant Unmet Need Further Supports Broad Clinical Development Campaign for Selinexor Conference Call Scheduled for Today at 8:30 a.m. ET NEWTON, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KP
Read more →KPTIKaryopharm to Present at Bank of America Merrill Lynch 2015 Healthcare Conference
NEWTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the Bank of America Merrill Lyn
Read more →KPTIKaryopharm to Report First Quarter 2015 Financial Results on May 11, 2015
NEWTON, Mass., May 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2015 financial results on Monday, May 11, 2015. Karyopharm's management team will host a conferenc
Read more →KPTIKaryopharm to Present Late-Breaking Data at American Association for Cancer Research Annual Meeting
NEWTON, Mass., April 17, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that two late-breaking abstracts describing the activity of selinexor (KPT-330), the company's lead drug candidate in development
Read more →KPTIKaryopharm Granted U.S. Composition-of-Matter Patent for Selinexor (KPT-330)
NEWTON, Mass., April 13, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This pat
Read more →KPTIKaryopharm Appoints Mikael Dolsten, MD, PhD to Its Board of Directors
NEWTON, Mass., April 1, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Mikael Dolsten, MD, PhD, President of Pfizer Worldwide Research and Development of Pfizer Inc., to the company'
Read more →KPTIKaryopharm to Present Data on Its Novel Oral PAK4 Allosteric Modulator (PAM) at the American Association for Cancer Research Annual Meeting
NEWTON, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that five abstracts describing the company's PAK4 allosteric modulators (PAMs) have been selected for presentation at the 2015 An
Read more →KPTIKaryopharm to Present Data on Oncology Pipeline at American Association for Cancer Research Annual Meeting
NEWTON, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that fourteen abstracts describing the activity of selinexor (KPT-330), the company's lead drug candidate in development for hema
Read more →KPTITargeting Disease at the Nuclear Pore Karyopharm Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Progress Initiated Multiple Registration-directed Trials and Presented Positive Selinexor
Karyopharm Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Progress Initiated Multiple Registration-directed Trials and Presented Positive Selinexor Clinical Data in 2014 Aggressive Selinexor Development Campaign Continues in 2015 Conference C
Read more →KPTIKaryopharm Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Progress
Initiated Multiple Registration-directed Trials and Presented Positive Selinexor Clinical Data in 2014 Aggressive Selinexor Development Campaign Continues in 2015 Conference Call Scheduled for today at 8:30 a.m. ET NEWTON, Mass., March 16, 2015 (GLOBE NEWSWIRE) -- Karyopharm T
Read more →KPTIKaryopharm to Report Fourth Quarter and Full Year 2014 Financial Results on March 16, 2015
NEWTON, Mass., March 9, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year ended 2014 financial results on Monday, March 16, 2015. Karyopharm's management team w
Read more →KPTIKaryopharm to Present at Leerink Partners Global Healthcare Conference
NEWTON, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the Leerink Partners Global He
Read more →KPTIKaryopharm Announces Orphan Designation Granted by FDA for Selinexor (KPT-330) in Multiple Myeloma
NEWTON, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, selinexor (KPT-330), has received orphan drug designation from the U.S. Food and Drug Administration
Read more →KPTIKaryopharm to Present at J.P. Morgan 33rd Annual Healthcare Conference
NEWTON, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the J.P. Morgan 33rd Annual He
Read more →KPTIRISK FACTORS Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in t
Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes
Read more →KPTIKaryopharm Announces Addition to the NASDAQ Biotechnology Index
NEWTON, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnol
Read more →KPTIKaryopharm Initiates Third Registration-Directed Clinical Trial of Oral Selinexor (KPT-330)
NEWTON, Mass., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of the SADAL study, (Selinexor and Dexamethasone in Aggressive Lymphoma), a registration-directed, Phase 2b study o
Read more →KPTIKaryopharm Presents Positive Clinical Data for Selinexor (KPT-330) in NHL Patients at ASH 2014 Annual Meeting
NEWTON, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its lead product candidate, Selinexor (KPT-330), a first-in-class, oral Selective In
Read more →KPTIKaryopharm Presents Positive Combination Data for Selinexor (KPT-330) in Multiple Myeloma Patients at ASH 2014 Annual Meeting
- Selinexor Demonstrates Synergy in Combination with Approved Therapies for Multiple Myeloma - - Durable Responses with Selinexor in Combination with Low-dose Dexamethasone in Heavily Pretreated Patients with Refractory Multiple Myeloma - - Anti-myeloma Activity with Selinexor
Read more →KPTIKaryopharm to Present at Oppenheimer 25th Annual Healthcare Conference
NEWTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Justin A. Renz, Executive Vice President and Chief Financial Officer of Karyopharm, is scheduled to present at the Oppenheimer
Read more →KPTIKaryopharm to Present Clinical Data Update for Selinexor (KPT-330) in Oncology
- Presentation to Include Discussion of Selinexor as Single-Agent and in Combination to Treat Hematological Malignancies - - Webcast Event Scheduled for Monday, December 8, 2014 at 8:30 p.m. PST - NEWTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nas
Read more →KPTIKaryopharm Announces Additional Orphan Designations Granted for Selinexor (KPT-330) by European Commission
NEWTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, Selinexor (KPT-330), has received orphan drug designation from the European Medicines Agency (EMA) of
Read more →KPTIKaryopharm Presents Data on Oncology Pipeline at EORTC-NCI-AACR Annual Meeting
- Selinexor Synergy with DNA Damage Inducing Treatments Provides Potential for Improved Clinical Outcomes - - XPO1 Occupancy Assay Developed to Evaluate Selinexor Binding to its Target and Predicts Drug Exposure - - Identification of Novel Mechanism PAK4 Allosteric Modulators w
Read more →KPTIKaryopharm Reports Third Quarter 2014 Financial Results and Highlights Recent Progress
- Reported Positive Phase 1 Clinical Data Demonstrating Early Signs of Activity for Selinexor in Several Solid Tumor Settings - - Initiated SIRTT, an Additional Registration-Directed Trial for Relapsed/Refractory Richter's Transformation - - Provides Preview on Several Presenta
Read more →KPTIKaryopharm Initiates Registration-Directed Clinical Study of Selinexor (KPT-330) in Patients With Richter's Transformation
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation (SIRRT) that is relapsed afte
Read more →KPTIKaryopharm Announces Data Presentations at American Society of Hematology Annual Meeting
NEWTON, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical and pre-clinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of
Read more →KPTIKaryopharm to Present at Credit Suisse 2014 Healthcare Conference
NEWTON, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the Credit Suisse 2014 Healthcare Confer
Read more →KPTIKaryopharm Appoints J. Scott Garland to Its Board of Directors
NEWTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa Inc., to the company's board of
Read more →KPTIKaryopharm to Report Third Quarter 2014 Financial Results on November 10, 2014
NEWTON, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company today announced it will report third quarter 2014 financial results on Monday, November 10, 2014. Karyopharm's management team will host a conferen
Read more →KPTIKaryopharm Expands Global Presence With European Subsidiary
NEWTON, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it has expanded its operational footprint with a wholly-owned European subsidiary and appointed Ran Frenkel, an international
Read more →KPTIKaryopharm Announces Clinical Data for Selinexor (KPT-330) in Advanced Solid Tumors
- Selinexor Demonstrates Clinical Activity in Prostate Cancer and other Solid Tumors - - Data from Ongoing Phase 1 Clinical Study Presented at ESMO 2014 - - Webcast Scheduled for Monday, September 29, 2014 at 4:30pm ET - NEWTON, Mass., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Karyop
Read more →KPTIKaryopharm to Host Conference Call to Discuss Selinexor (KPT-330) Data Presented at ESMO 2014
- Phase 1 Clinical Data in Prostate Cancer and Other Solid Tumors - - Conference Call and Interactive Webcast Scheduled for Monday, September 29, 2014 at 4:30pm ET - NEWTON, Mass., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage p
Read more →KPTIKaryopharm Announces Three Clinical Data Presentations at ESMO 2014
NEWTON, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical and preclinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of
Read more →KPTIKaryopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer
NEWTON, Mass., Aug. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics Reports Second Quarter Financial Results for 2014
NEWTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm to Present at the Wedbush 2014 Life Sciences Management Access Conference
NEWTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm to Host Second Quarter 2014 Earnings Call on August 7, 2014
NEWTON, Mass., Aug. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on nuclear transport targets, today announced that it will host a conference call on Thursday, August 7, 2014 at 4:30 p.m. EDT to report its
Read more →KPTIKaryopharm Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock
NATICK, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 397,087 shares of its common stock a
Read more →KPTIKaryopharm Initiates Registration-Directed, Randomized Study of Selinexor (KPT-330) in Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NATICK, Mass., June 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Announces: FDA Considers the Effectiveness and Safety Technical Sections Complete to Support Conditional Approval for the New Animal Drug Application for Verdinexor (KPT-335) to Treat Lymphoma in Client Owned Dogs
NATICK, Mass., June 16, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel, first-in-class drugs directed against nuclear transport targets for the treatment of cancer and
Read more →KPTIKaryopharm Announces First Combination Data of Selinexor With Low-Dose Dexamethasone in Heavily Pretreated Multiple Myeloma Patients
NATICK, Mass., June 13, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm's lead selective inhibitor of nuclear export (SIN
Read more →KPTIKaryopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study)
NATICK, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Updates Data for Selinexor in Solid Tumors at 2014 ASCO Annual Meeting
NATICK, Mass., June 2, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients
Read more →KPTIKaryopharm Provides Data Update for Selinexor in Non-Hodgkin's Lymphoma and Acute Myeloid Leukemia at 2014 ASCO Annual Meeting
NATICK, Mass., May 31, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients
Read more →KPTIKaryopharm to Webcast Investor & Analyst Briefing on Monday, June 2, 2014
NATICK, Mass., May 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Announces Six Data Presentations at the 19th Congress of the European Hematology Association
NATICK, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the upcoming presentation of clinical and preclinical data highlighting its novel first-in-class drug candidates directed against n
Read more →KPTIKaryopharm Announces Second Orphan Drug Designation for Selinexor in Diffuse Large B-Cell Lymphoma (DLBCL)
NATICK, Mass., May 20, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Receives Orphan Drug Designation for Acute Myeloid Leukemia (AML)
NATICK, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics Reports First Quarter Financial Results for 2014
NATICK, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and oth
Read more →KPTIKaryopharm to Present at Upcoming Healthcare Conferences
NATICK, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and oth
Read more →KPTIKaryopharm Announces Five Clinical Data Presentations at ASCO 2014
NATICK, Mass., April 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and
Read more →KPTIKaryopharm Announces a Phase 1 Trial of Selinexor (KPT-330) in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
NATICK, Mass., April 21, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and
Read more →KPTIKaryopharm Announces Initiation of a Phase 1 Study of Decitabine (Dacogen(R)) and Selinexor (KPT-330) in Acute Myeloid Leukemia (AML)
NATICK, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and
Read more →KPTIKaryopharm Appoints Chris Primiano as General Counsel
NATICK, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and
Read more →KPTIKaryopharm Therapeutics to Present at 13th Annual Needham Healthcare Conference
NATICK, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Therapeutics Reports 2013 Year-End Financial Results and Provides Update on Clinical Development Plans
NATICK, Mass., March 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Therapeutics Announces Initiation of an Investigator Sponsored Phase 1 Dose Escalation Study of Its Lead Drug Candidate Selinexor (KPT-330) in Singapore
NATICK, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Therapeutics Announces Nine Presentations on its Selective Inhibitors of Nuclear Export (SINE) Compounds and PAK4 Inhibitors at the American Association of Cancer Research (AACR) Meeting
NATICK, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Therapeutics to Present at Upcoming Healthcare Conferences in February
NATICK, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics Inc. [KPTI] to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. [KPTI], a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major d
Read more →KPTIKaryopharm Therapeutics Presents Clinical Data on Selinexor (KPT-330) in Colorectal Cancer From Ongoing Phase 1 Study and Preclinical Data on Novel PAK4 Inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium
- Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients - - Potential Anti-Proliferative Activity of Novel PAK4 Inhibitor Seen in Preclinical Pancreatic Cancer Model - NATICK, Mass., Jan. 22, 2014 (GLOBE NEWSWIRE) -- Karyop
Read more →KPTIKaryopharm Therapeutics Announces Data Presentations at American Society of Clinical Oncology Annual Gastrointestinal Cancers Symposium
NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Therapeutics Announces Award of Grant From National Multiple Sclerosis Society to Further Develop Selective Inhibitors of Nuclear Export (SINE) Compounds
NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics Announces Submission of New Animal Drug Application Effectiveness and Safety Sections for Novel, Oral, Small-Molecule Selective Inhibitor of Nuclear Export (SINE) Verdinexor for Canine Lymphoma to FDA's Center for Veterinary Medicine
NATICK, Mass., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major dise
Read more →KPTIKaryopharm Therapeutics Added to Russell 3000(R) and Russell 2000(R) Indexes
NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering
NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and o
Read more →KPTIKaryopharm Therapeutics Presents Promising Data for Selinexor, an Oral, First-in-Class Selective Inhibitors of Nuclear Export (SINE) Compound, in Hematologic Malignancies at 2013 ASH Annual Meeting
NATICK, Mass., Dec. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics Announces Highlights From Poster Presentations on Selective Inhibitors of Nuclear Export (SINE) Compounds in Hematologic Malignancies at 2013 ASH Annual Meeting
NATICK, Mass., Dec. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference
NATICK, Mass., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics to Host Investor Reception and Webcast at the 2013 American Society of Hematology Annual Meeting
NATICK, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and ot
Read more →KPTIKaryopharm Therapeutics Announces Data Presentations at American Society of Hematology Annual Meeting
NATICK, Mass., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other
Read more →KPTIKaryopharm Therapeutics Announces Pricing of Initial Public Offering
NATICK, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced
Read more →KPTIKaryopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the Use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in Preclinical Models of Autoimmune Disease
NATICK, Mass., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. announces oral presentations at the 2013 ACR Annual Meeting on the use of its oral SINE XPO1 antagonists in preclinical models of Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). Precli
Read more →KPTIKaryopharm Therapeutics Files Registration Statement for Proposed Initial Public Offering
NATICK, Mass., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today
Read more →KPTIKaryopharm Therapeutics Announces Appointment of Garen Bohlin to Board of Directors
NATICK, Mass., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced
Read more →KPTIKaryopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research Conferences
NATICK, Mass., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of cancer and other major diseases, announced that a poster titled "Novel inhi
Read more →KPTIKaryopharm Therapeutics Secures $19 Million in Series B Financing Extension
- Additional funds to expand the clinical development of Selinexor (KPT-330), including planned Phase 2/3 clinical trials - - Total Series B commitment exceeds $67 million - NATICK, Mass., July 31, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmac
Read more →KPTIKaryopharm Therapeutics Initiates a Phase 1b Food-Effect Clinical Trial With the Novel Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Sarcomas
NATICK, Mass., July 31, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of cancer and other major diseases, today announced the initiation of a Phase
Read more →KPTIKaryopharm Therapeutics Announces Appointment of Paul Brannelly as Senior Vice President of Finance and Administration
NATICK, Mass., June 13, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today announced that Paul Brannelly has joined the company as Senior Vice President, Finance and Administration. Mr. Brannelly brings over 13
Read more →KPTIKaryopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual Meeting
NATICK, Mass., June 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today announced the presentation of clinical data from an ongoing phase 1 clinical trial of its lead oral SINE selinexor (KPT-330) in patients
Read more →KPTIKaryopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA Congress
NATICK, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that data for its lead compound KPT-330 against advanced chronic myeloid leukemia (CML) will be presented in the CML Biology oral abs
Read more →KPTIKaryopharm Therapeutics Raises $48.2 Million in Series B Financing
NATICK, Mass., May 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today announced that it has raised $48.2 million in a Series B financing. The funds will be used to advance the Company's pipeline of novel Sel
Read more →KPTIKaryopharm Therapeutics to Present Clinical Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual Meeting
NATICK, Mass., May 15, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that clinical data for its lead drug candidate, KPT-330, in patients with advanced solid tumors will be presented in the Developmenta
Read more →KPTIKaryopharm Therapeutics to Present Data on Selective Inhibitors of Nuclear Export (SINE) to Treat Influenza and HIV at International Congress on Antiviral Research (ICAR)
NATICK, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces an oral and poster presentation at the 26th International Conference on Antiviral Research (ICAR) in San Francisco, California, May 11
Read more →KPTIKaryopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR) Meeting
NATICK, Mass., March 26, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces fifteen (15) poster presentations covering its Selective Inhibitors of Nuclear Export (SINE), oral small molecule XPO1/CRM1 antagon
Read more →KPTIKaryopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & Development
NATICK, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces that Ken Weg and Barry Greene have joined its Board of Directors. In addition, Founder and Chief Scientific Officer (CSO) Sharon Shac
Read more →KPTIKaryopharm Therapeutics Initiates Treatment of Patients With Acute Myeloid Leukemia (AML) in Phase 1 Trial With Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)
NATICK, Mass., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced the dosing of patients with AML in the ongoing Phase 1 clinical trial of KPT-330 in patients with advanced hematologic malignancies.
Read more →KPTIKaryopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL)
NATICK, Mass., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of dogs with newly diagnosed or relapsed lymphoma in clinical trial KARYO-2. KARYO-2 is designed to support an application of
Read more →KPTIKaryopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) Meeting
NATICK, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces eight presentations by collaborators covering its SINE CRM1 antagonists at the ASH meeting on December 8-11, 2012, in Atlanta, Georg
Read more →KPTIKaryopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
NATICK, Mass., Nov. 12, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the treatment of systemic lupus erythematosus. Jennifer Anolik, MD, PhD, A
Read more →KPTIKaryopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer
NATICK, Mass., Oct. 31, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces the publication of several articles covering its SINE compounds in a variety of cancers. Because SINE CRM1 antagonists return multiple tumor
Read more →KPTIKaryopharm Therapeutics Recognizes the Contributions of Co-Founder Ronald DePinho, MD
NATICK, Mass., Oct. 31, 2012 /PRNewswire/ -- Ronald A. DePinho, M.D., a co-founder and board member of Karyopharm Therapeutics Inc. since 2009, elected to resign from the company's board of directors, effective Oct. 10, 2012, at a time when the company has achieved a "strong base
Read more →KPTIKaryopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
NATICK, Mass., Aug. 1, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced publication of preclinical models utilizing their proprietary SINE compounds in AML. SINEs specifically and irreversibly inhibit the nucl
Read more →KPTIKaryopharm Therapeutics Announces Appointment of Co-founder Dr. Ronald DePinho to the National Academy of Sciences
NATICK, Mass., May 8, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces that co-founder Ronald A. DePinho MD, President of MD Anderson Cancer Center, has been appointed to the National Academy of Sciences. (Lo
Read more →KPTIKaryopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
NATICK, Mass., March 7, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces nine presentations covering its Selective Inhibitors of Nuclear Export (SINE), oral small molecule CRM1 antagonists, at the AACR meeting
Read more →KPTIKaryopharm Therapeutics Announces Presentations by Seven Collaborators Showing Major Progress in Advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at American Society of Hematology (ASH) Meeting
NATICK, Mass., Nov. 8, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces seven presentations by collaborators covering its Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein at the Ame
Read more →KPTIKaryopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
NATICK, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Ch
Read more →KPTIKaryopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
NATICK, Mass., Oct. 11, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has initiated an exclusive collaboration in the area of Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein with the Rega
Read more →KPTIKaryopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
NEWTON, Mass., Jan. 5, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a pioneer and leader in the new field of nuclear transport modulators, announces the recruitment of a highly experienced cancer drug developer, Michael G. Kauffman, MD, PhD, as its Chief Executive Officer.
Read more →KPTIKaryopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
NEWTON, Mass., Nov. 3, 2010 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $20M Series A financing. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a b
Read more →Competitive Position
How KPTI ranks across every disease it competes inCompetitive Position is a premium feature
See how KPTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial